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2 
Abstract 
 
Limited oxygen availability (hypoxia) influences cell migration and invasion, but 
the underlying mechanisms are poorly understood. Much of the cellular response 
to hypoxia is regulated by a family of Hypoxia Inducible Factor (HIF) prolyl 
hydroxylases (PHD1-3), each of which is thought to regulate specific pathways. 
Their activity is dependent on the availability of oxygen and -ketoglutarate but 
despite intensive studies their activity in vivo and their substrates are poorly 
defined. 
In this study we performed a quantitative proteomic screen to identify new 
substrates of PHDs. Co-immunoprecipitations using FLAG-tagged PHDs were 
performed under hypoxia to trap the enzyme-substrate interactions, and binding 
partners were identified by mass spectrometry. Actin was identified to interact 
with PHD3 specifically under hypoxia. Subsequently two defined prolyl residues 
in -actin were shown to be hydroxylated. Hypoxia-induced rearrangement of 
the actin cytoskeleton was shown to be dependent on PHD3 activity as a 
knockdown of PHD3 was sufficient to increase the intracellular G- to F-actin 
ratio. An increase in cell migration and invasion was also found to be dependent 
on PHD3 activity. Mutation of both hydroxylated prolyl residues led to a similar 
phenotype regarding actin rearrangement and cell migration. Using constantly 
active HIF-mutants, we could show that these PHD3-dependent pathways are 
independent of HIF. 
All together, this study shows a pro-invasive pathway linking HIF-independent 
oxygen-sensing pathways and actin signalling. However, the mechanism of how 
hypoxia-induced actin rearrangement leads to increased migration and invasion 
remains to be elucidated. 
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1 Introduction 
1.1 Tumorigenesis and hypoxia 
Cancer is thought to be one of the most frequent diseases in the developed 
world with an estimated one in three persons affected by it [1]. Tumorigenesis is 
a multistep process, in which cancer cells accumulate genetic alterations in 
pathways that control cell growth and proliferation leading to a selective growth 
advantage. Six essential alterations were originally described to contribute to 
tumour formation. These hallmarks of cancer were described as self-sufficiency 
in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis 
and tissue invasion and metastasis [2]. Recently, additional hallmarks of cancer 
were proposed to include evasion of immune surveillance as well as several 
stress phenotypes including metabolic, proteotoxic, mitotic, oxidative and DNA 
damage stress [3, 4]. Metabolic stress is induced by high glucose uptake and 
elevated rates of glycolysis which is used as main source of energy production in 
tumours. An imbalance in the stoichiometry of protein complex subunits as well 
as improper folding of proteins lead to activation of the heat shock response in 
tumours which is evidence of proteotoxic stress. Chromosome mis-segregation 
and chromosome instability are linked to mitotic stress whereas the elevated 
levels of reactive oxygen species (ROS) that are highly reactive and contribute to 
DNA damage lead to oxidative stress in tumours. Rapidly growing tumours can 
outgrow their vascular system leading to low oxygen (hypoxia), low pH and 
nutrient starvation within these tumours (for reviews: [5-9]). Oxygen is only able 
to diffuse 100-180 m from the nearest capillary to cells before is it fully 
metabolised. Therefore many solid tumours contain areas of hypoxia compared 
to the surrounding normal tissue. Hypoxia provides a strong selective pro-
tumorigenic pressure and hypoxic tumours are often found to be more aggressive 
and metastatic. As shown in Figure 1.1 cells adapt to the hypoxic 
microenvironment by inducing adaptive mechanisms that influence processes 
involved in regulating the above named hallmarks of cancer either directly or 
indirectly as various transcription factors were shown to be hypoxia-responsive 
[10, 11]. For example, hypoxia influences pathways involved in angiogenesis, 
glucose metabolism, cell proliferation and survival as well as migration. The 
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master transcriptional regulator of hypoxia- inducible genes is the heterodimeric 
transcription factor, Hypoxia Inducible Factor (HIF). HIF is composed of an 
oxygen regulated -subunit and an oxygen-insensitive -subunit. 
 
Figure 1.1: Processes that are influences by hypoxia [12] 
Genes that are transcriptionally activated by HIF-1. Genes that are involved in many 
processes are transcriptionally activated by HIF-1. ADM, adrenomedullin; ALDA, aldolase A; 
ALDC, aldolase C; AMF, autocrine motility factor; CATHD, cathepsin D; EG-VEGF, 
endocrinegland-derived VEGF; ENG, endoglin; ET1, endothelin-1; ENO1, enolase 1; EPO, 
erythropoietin; FN1, fibronectin 1; GLUT1, glucose transporter 1; GLUT3, glucose 
transporter 3; GAPDH, glyceraldehyde-3-P-dehydrogenase; HK1, hexokinase 1; HK2, 
hexokinase 2; IGF2, insulin-like growth-factor 2; IGF-BP1, IGF-factor-binding-protein 1; IGF-
BP2, IGF-factor-binding-protein 2; IGF-BP3, IGF-factor-binding-protein 3; KRT14, keratin 14; 
KRT18, keratin 18; KRT19, keratin 19; LDHA, lactate dehydrogenase A; LEP, leptin; LRP1, 
LDL-receptor-related protein 1; MDR1, multidrug resistance 1; MMP2, matrix 
metalloproteinase 2; NOS2, nitric oxide synthase 2; PFKBF3, 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase-3; PFKL, phosphofructokinase L; PGK 1, 
phosphoglycerate kinase 1; PAI1, plasminogen-activator inhibitor 1; PKM, pyruvate kinase 
M; TGF-, transforming growth factor-; TGF-3, transforming growth factor-3; TPI, 
triosephosphate isomerase; VEGF, vascular endothelial growth factor; UPAR, urokinase 
plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, vimentin. 
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Tumour hypoxia is often correlated with tumour aggressiveness and resistance to 
radio- and chemotherapies [13, 14]. It is therefore important to understand 
hypoxic signalling to improve treatments and patient survival. Several types of 
tumours were identified with loss of function mutations in several genes involved 
in oxygen-sensing pathways, which helped to improve our understanding of 
oxygen sensing pathways. These tumours include: Loss of function mutations of 
the E3-ligase pVHL found in clear cell renal carcinomas as well as mutations in 
succinate dehydrogenase (SDH) and fumarate hydrolase (FH) leading to inhibition 
of HIF prolyl hydroxylase (PHD) activity in paragangliomas, 
phaeochromocytomas, leiomyomas and renal cell cancer. Recently it was shown 
that nuclear localisation of PHD2 can increase anchorage-independent growth of 
cancer cells [15] whereas mutations in PHD2 were linked to paragangliomas 
suggesting that PHD2 may act as tumour suppressor [16, 17]. A better 
understanding of the mechanisms leading to formation of these tumours will 
help to design better treatments. 
 
1.2 Superfamily of Fe(II)- and -ketoglutarate-dependent 
dioxygenases 
The cellular response to hypoxia is mostly mediated by Hypoxia Inducible Factor 
(HIF) prolyl hydroxylases (PHD), which belong to a superfamily of Fe(II)- and -
ketoglutarate-dependent dioxygenases. PHDs catalyse the hydroxylation of 
specific prolyl residues in an oxygen-dependent fashion but retain low affinity to 
oxygen making them good oxygen sensors. This is a unique function of PHDs as 
activity of other prolyl hydroxylases such as collagen prolyl-4-hydroxylases is 
preserved under hypoxia [18]. Hydroxylation of proline residues is a well known 
posttranscriptional modification of a number of secreted proteins such as 
collagen become enzymatically hydroxylated at prolyl residues in the 
endoplasmatic reticulum. Hydroxylation of collagen is important for the stability 
of collagen fibres (for reviews: [19, 20]). However cellular oxygen sensing is the 
first example that protein hydroxylation is used in intracellular signalling.  
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1.2.1 HIF-prolyl hydroxylases (PHD) 
Mammalian PHDs were originally identified as homologues of the Caenorhabditis 
elegans (c.elegans) gene product egln [21, 22]. In c. elegans egl- 9 acts as prolyl 
hydroxylase that targets HIF1 for degradation via the pVHL- ubiquitin- 
proteasome pathway (Figure 1.2) [22].  
 
 
 
Figure 1.2: Regulation of HIF-1stability by oxygen-sensitive proline hydroxylation [23]. 
Under normal oxygen concentrations, HIF-1is hydroxylated at Pro402 and Pro564 by HIF 
prolyl hydroxylases. The reaction requires O2 and iron(II) and utilizes peptidyl proline and -
ketoglutarate as co-substrates; ascorbate is a cofactor needed for maximal activity. 
Hydroxyproline, succinate, and CO2 are produced. Proline hydroxylation of HIF-1increases 
its affinity for pVHL, which targets HIF-1for ubiquitination and degradation. Under hypoxic 
conditions, prolyl hydroxylase activity decreases and non-hydroxylated HIF-1is free to 
accumulate in the nucleus where it associates with the HIF -subunit to activate 
transcription of target genes. 
 
The name of the protein egl- 9 derives from an egg laying defective phenotype 
in c. elegans. As these hydroxylases seemed to be a conserved gene family 
among species, human homologues were identified by sequence homology using 
a candidate gene approach and subsequently via biochemical purification of 
hydroxylase activity [18, 22, 24]. Only a single member of this family was found 
in c. elegans whereas three paralogous transcripts could be identified in human. 
The three mammalian isoforms were identified by different groups and are 
therefore known by different nomenclatures PHD1/2/3, EglN2/1/3 or HPH3/2/1 
respectively [18, 21, 22, 24]. All three PHDs have a conserved genomic structure 
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with five coding exons. The translated proteins contain a conserved C-terminal 
region responsible for their hydoxylase activity and highly variable N-termini. 
PHD2 seems to be the ancestral form of the protein [21]. PHDs show a 42-59% 
sequence similarity to each other [18, 22, 24] and have different sizes: PHD1 is 
43.6 kDa, PHD2 46 kDa whereas PHD3 is much smaller with 27.3 kDa. Later, a 
forth human prolyl-4-hydroxylase was identified in a database search [25, 26]. 
The sequence of this hydroxylase is more closely related to collagen 
hydroxylases than PHDs, but its activity seemed to decrease under hypoxia. It 
was found to be a transmembrane protein localised in the ER membrane with its 
catalytic site inside the lumen. However not much is known about its function 
and we will only refer to PHD1-3 in the following sections. 
1.2.1.1 Enzyme structure and reaction mechanism 
X-ray crystallographic analysis from different dioxygenases gave an insight into 
their structure and function [27]. Recently, the catalytic domain of PHD2 was 
crystallised as a homotrimer in complex with an inhibitor or in a complex with a 
peptide of the HIF1 degradation domain [28, 29]. Dioxygenases consist of a core 
of eight - strands that are folded into a -barrel jelly roll motif. The enzymes 
show a highly conserved two-histidine, one-carboxylate motif to coordinate 
Fe(II) binding at the catalytic site.  
PHDs as well as dioxygenases in general use - ketoglutarate and molecular 
oxygen as co-substrates and require Fe(II) and ascorbate for their activity. 
Dioxygensases seem to work by a common mechanism as was shown for the 
asparaginyl hydroxyase FIH (Figure 1.3): The binding of the protein substrate, -
ketoglutarate and molecular oxygen is followed by oxidative decarboxylation of 
-ketoglutarate and splitting of molecular oxygen to give succinate and CO2 as 
well as a hydroxyprolyl residue [30]. The binding of - ketoglutarate and the 
prime protein substrate is reversible.  
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Figure 1.3: Reaction mechanism of prolyl hydroxylation [31] 
 
As the activity of PHDs is mainly regulated by oxygen supply with their kM for 
oxygen near physiological oxygen levels, PHDs are thought to function as 
molecular oxygen sensors [22, 32]. However, other factors such as availability of 
-ketoglutarate also influence their activity. Reduction in hydroxylase activity 
was detected when oxygen concentration was reduced from 20% to 10% and 
progressive inhibition was observed at lower oxygen tensions [22]. TCA cycle 
intermediates such as succinate and fumarate were shown to inhibit PHD activity 
[33, 34]. However elevated levels of -ketoglutarate can overcome the 
inhibition of PHD activity by succinate and fumarate as well as by hypoxia [35, 
36]. Therefore the intracellular ratio of -ketoglutarate to succinate, meaning 
the ratio of co-substate to product, is important for PHD activity. Hypoxia 
mimetics such as desferroxamine or divalent metals such as Co2+, Mn2+ or Zn2+ 
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can block enzyme activity by blocking iron availability. Ascorbate appears to be 
important for enzyme activity, however its role is not quite clear [37].  
1.2.1.2 Intracellular localisation and abundance 
PHD isoforms are ubiquitously expressed but expression levels vary between the 
isoforms and between different cell types [38, 39]. PHD2 is widely expressed in 
all cell types, PHD1 levels are high in testis whereas PHD3 is most abundant in 
the heart. Under hypoxia, levels of PHD2 and PHD3 are upregulated whereas 
PHD1 levels are independent of ambient oxygen concentrations [40, 41]. 
Subsequently PHD2 as well as PHD3 were shown to be upregulated in a HIF-
dependent manner as their promoters were shown to include hypoxia-response 
elements (HRE) [42, 43]. This upregulation in PHD2 and PHD3 was suggested to 
be an important feedback mechanism for reoxygenation [44]. However, the 
intracellular abundance of PHD1 and PHD3 was shown to be dependent on other 
factors apart from oxygen levels adding to the complexity of regulating PHDs 
levels and activity. PHD1 and 3 were shown to be targeted for proteasomal 
degradation by the E3 ubiquitin ligases Siah2 [45]. Siah2 is upregulated under 
hypoxia inducing degradation of PHD1 and 3 under these conditions.  
PHDs show distinct intracellular localisation: PHD1 localises predominantly to 
the nucleus, PHD2 to the cytoplasm whereas PHD3 is evenly distributed between 
both compartments [40]. This localisation is not influenced by the oxygen 
supply. Localisation is determined by the presence of a nuclear localisation 
signal (NLS) in PHD1, or a region responsible for nuclear export in PHD2 [46]. 
Importins  are involved in regulating the localisation of PHD1. PHD2 is able to 
shuttle between the nucleus and the cytoplasm using the CRM1 export receptor 
and an unknown import receptor but it is thought to be actively excluded from 
the nucleus leading to its cytoplasmic localisation [46, 47]. Recently, PHDs were 
suggested to form larger protein complexes as they were shown to interact with 
scaffolding proteins. PHD3 was shown to interact with the chaperonin TRiC 
which is thought to play a role in formation of multiprotein complexes [48] as 
well as with the WD-repeat protein Morg1 which can act as a molecular scaffold 
[49]. PHD3 was also suggested to be able to form homo- and heteromultimers 
with other PHDs especially under hypoxia which affects their activity and 
susceptibility to Siah2-dependent degradation [50]. The protein OS-9 was shown 
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to interact with HIF1 as well as PHD2 and PHD3 [51]. The formation of this 
ternary complex promotes hydroxylation of HIF and ultimately regulates HIF 
levels. Larger complexes seem to be involved in these pathways however the 
functions of these interactions remain unclear. 
1.2.1.3 Substrate specificity of PHDs 
PHDs seem to show different substrate specificities, but it is unknown how the 
different isoforms distinguish between substrates [52]. A conserved LXXLAP 
motif is thought to be the substrate binding motif for prolyl hydroxylases in 
general but mutations in all positions can be tolerated apart from the proline 
that is hydroxylated [22, 53, 54]. Apart from this core binding motif, distal 
residues from the hydroxylation site such as a leucine ten residues downstream 
of the hydroxylated prolyl residue seem to be important for substrate binding 
and to be involved in the recruitment of the hydroxylase [55, 56]. Acidic 
residues are found in the vicinity of the hydroxylacceptor proline and they seem 
to be involved in substrate binding as well [57]. These residues are either found 
N- terminal or C- terminal to the hydroxyproline. Recently, a region relatively 
far from the catalytic site on PHDs was shown to be important for substrate 
preference [58]. This region shows moderate conservation among the family 
members which could account for target preferences [29, 59]. In general, 
substrate specificity seems to be provided by multiple interactions and a rigid 
consensus sequence might be absent.  
1.2.1.4 Functions of PHD isoforms 
Distinct functions have been described for each of the PHD isoforms: the best 
studied example is their role in the degradation of the oxygen regulated -
subunit of the heterodimeric transcription factor, HIF. HIF is composed of an 
oxygen-regulated -subunit and an oxygen-insensitive -subunit and is the 
master transcriptional regulator of hypoxia- inducible genes (for reviews: [30, 
31, 37, 60-62]). Proteasomal degradation of the -subunit is dependent on the 
hydroxylation of two specific prolyl residues [63, 64]. Hydroxylation of these 
prolyl residues promotes binding to pVHL, the substrate recognition unit of an E3 
ubiquitin-ligase complex, and its subsequent degradation by the ubiquitin-
proteasome pathway leading to low steady state levels of HIF under normoxia. 
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Non-hydroxylated HIF is not recognized by the pVHL complex leading to its 
accumulation under low oxygen conditions and its subsequent translocation into 
the nucleus. In the nucleus HIF dimerizes with the -subunit and then binds to 
hypoxia- response elements (HRE) within the promoters of its target genes. 
Although HIF1 is stabilised within minutes after exposure to hypoxia, most of 
the cellular response to HIF is determined by transcription. PHD2 plays a non-
redundant role in this pathway as loss of PHD2 activity is sufficient to stabilise 
HIF1 under normoxia [65]. PHD1 and PHD3 have little or no effect on the 
stability of HIF1.  
Beside their importance in regulating HIF levels, PHDs have been shown to be 
involved in other pathways: Loss of PHD2 in tumours leads to increase in nuclear 
factor kappa B (NFB) activity, subsequently to an increase interleukin-8 (IL-8) 
and angiogenin and ultimately to an increase in blood vessels. Therefore PHD2 
influences tumour angiogenesis in a NF-B-dependent manner [66]. PHD2 also 
associates with the tumour suppressor protein inhibitor of growth family member 
4 (ING4) regulating HIF activity [67]. ING4 does not seem to be a substrate of 
PHD2 as the interaction does not seem to be affected by hydroxylase activity or 
affect HIF stability but rather be involved in recruitment of transcriptional 
repressors. In a yeast two-hybrid screens PHD2 was identified to interact with 
the peptidyl prolyl cis/trans isomerase FK506-binding protein 38 (FKBP38), which 
seems to be involved in PHD2 protein regulation [68], and the melanoma antigen 
11 (MAGEA11) leading to inhibition of PHD activity [69]. PHD3 is involved in 
neuronal cell death following the withdrawal of neuronal growth factor (NGF) 
[70]. It was shown to act downstream of c-Jun in this pathway and upstream of 
the motor protein kinesin KIF1B through an HIF-independent pathway [71]. 
During skeletal muscle differentiation PHD3 interacts with and stabilises 
myogenin [72]. The interaction is thought to prevent myogenin from 
ubiquitination and degradation via the ubiquitin-proteasome system. The 
underlying pathway was later shown to be HIF-independent but PHD3 appears 
regulate NF-B [73]. In a yeast two-hybrid system the activating transcription 
factor-4 (ATF4) was identified as a new interaction partner of PHD3 which 
regulates ATF4 stability [74]. Under hypoxia PHD3 forms a complex with PRP19, 
a multifunctional protein playing a role in splicing, ubiquitination and cell 
growth, under hypoxia inhibiting cell death during the hypoxic response [75]. 
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Although a role of PHD3 has been described in these different pathways, PHD3 
substrates remain elusive. However, recently PHD3 was shown to hydroxylate 
the 2-adrenergic receptor [76]. Hydroxylation of the receptor led to its 
degradation via the ubiquitin-proteasome system. PHD1 was shown to inhibit 
IB-kinase  (IKK) influencing NFB activity [77]. NFB is activated under 
hypoxia through a PHD1-dependent pathway that involves increased expression 
and activation of IKK leading to phosphorylation-dependent degradation of IB 
and liberation of NFB. The pathway appears to be dependent on a prolyl 
residue located in a LXXLAP motif in IKK. Loss of PHD1 leads to neuroprotection 
against cell death following oxidative stress using HIF-independent pathways [78] 
and to protection of skeletal muscles and hepatocytes against 
ischemia/reperfusion injury through metabolic regulation [79, 80]. Furthermore, 
PHD1 controls cyclin D1 levels in estrogen-dependent tumorigenesis [81]. 
Inactivation of PHD1 decreased cyclin D1 levels suppressing mammary gland 
proliferation in a HIF-independent manner. Regulation appears to be on the 
transcriptional level of cyclin D1. PHD1 and PHD2 are able to interact with and 
regulate the large subunit of RNA Polymerase II [82]. A region in the large 
subunit of RNA polymerase II (Rpb1) was identified to have sequence and 
structural similarity with the HIF1-domain that binds pVHL. Binding of Rpb1 to 
pVHL appeared to be hydroxylation dependent [83]. 
Confirming differential functions of each of the PHD isoforms different 
phenotypes were observed in PHD knockout mice. Underlining the importance of 
PHD2 in development PHD2-/- mice showed embryonic lethality whereas PHD1-/- 
and PHD3-/- mice were viable. PHD2-/- embryos died between days E12.5 and 
E14.5 with severe defects in heart and placenta [84]. PHD3-/- mice showed a 
phenotype in the sympatho-adrenal system. PHD3 was shown to have an 
important role in regulating the development of the sympatho-adrenal system in 
a partially HIF2-dependent manner [85, 86]. PHD3 appears to increase NGF-
dependent neurite growth though less functional. As mentioned above PHD1-/- 
mice revealed the involvement of PHD1 in metabolic regulation in skeletal 
muscles and hepatocytes [79, 80]. Loss of PHD1 lowers oxygen consumption in 
skeletal muscles by shifting to a more anaerobic metabolism. Loss of PHD1 was 
associated with an increase in concentration of the nuclear receptor peroxisome 
proliferators-activated receptor (Ppar) leading to increase in pyruvate 
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dehydrogenase kinase 1 and 4 (PDK) gene transcription. PDKs negatively regulate 
the pyruvate dehydrogenase complex restricting the entry of glycolytic 
intermediates into the tricarboxylic acid cycle (TCA) cycle. Loss of PHD1 impairs 
oxidative muscle performance but provides protection against ischemia through 
reducing oxidative stress. Some of these functions appear to be HIF-independent 
but substrates of PHDs in these pathways have so far proved difficult to identify 
and are therefore mostly unknown. 
 
1.3 Hypoxia-induced metastasis 
Hypoxic tumours show an increased potential to form metastases. Numerous 
theories exist to explain metastasis, however most agree that it is a 
multifaceted process requiring modifications of the tumour cells and their 
microenvironment. Many aspects of metastasis are not fully understood, 
especially when and how cells move away from the primary tumour and how 
efficient these cells can proliferate at distant sites. However, it is known that 
metastasis involves some distinct processes such as local invasion of cells leading 
to intravasation into the lymphatic or vascular system, extravasation into distant 
organs and survival and proliferation at the distant site (Figure 1.4) [87].  
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Figure 1.4: Key steps in metastasis.  
In order to metastasise, a malignant cell must dissociate from the primary tumor and 
intravasate into the vascular or lymphatic systems by degrading and migrating through the 
basement membrane and extracellular matrix. Once in the lymph or the blood streams, this 
cell must evade the host immune system, migrate and home into its target site, and 
extravasate out of the circulation. The cell must overcome both anchorage-dependent 
growth and the ability to senescence at this distant site, while proliferating and inducing 
angiogenesis to nourish its own growth [88]. 
 
In order to be able to break away from the primary tumour cellular behaviour 
has to be altered resulting in changed adhesive properties, change in polarity, 
activation of motility and resistance to anoikis [89]. Some of these processes can 
be influenced by hypoxia. A number of proteins involved in progression of 
metastasis were shown to be HIF-target genes (Figure 1.1) such as vimentin, 
fibronectin, matrix metalloproteinase 2 (MMP2), urokinase plasminogen activator 
receptor (uPAR), receptor kinase c-Met and the cytokine receptor CXCR4 [90]. 
These proteins play a part in different phases of the metastatic progression. For 
example, expression of CXCR4 is suggested to be  important for homing at 
distant sites, connective tissue growth factor (CTGF) promotes anchorage-
independent cell growth and uPAR is involved in degradation of various proteins 
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in the extracellular matrix (ECM) [88, 91]. Another protein involved in changes in 
the ECM, namely lysyl oxidase (LOX), was found to be regulated in a HIF-
dependent fashion [92]. LOX is important for crosslinking collagen and elastin in 
the extracellular matrix. Increased LOX expression was linked to changes in the 
actin cytoskeleton as well as regulation of focal adhesions. Upregulation of c-Met 
leads to sensitizing cells to its ligand hepatocyte growth factor (HGF). HGF-
induced Met activation switches on an invasive programme that promotes 
extracellular matrix degradation, activates cell dissociation and cell migration 
[93]. One hallmark of invasion is the loss of cell-cell contacts, which is usually 
marked by loss of E-cadherin. Expression of E-cadherin and HIF were shown to be 
mutually exclusive [94]. Furthermore, hypoxia induces the expression of integrin 
1 (ITGB1) promoting wound healing in the intestinal submucosa [95] whereas it 
suppresses expression of 5 integrin inducing anoikis resistance and anchorage-
independent growth [96].  
1.3.1 Modes of invasion 
In order to metastasise to distal sites, tumour cells have to invade into 
surrounding tissues of the primary tumour. Single cells are able to invade in 
different modes, either in a mesenchymal (elongated) or in an amoeboid 
(rounded) pattern [97, 98]. Mesenchymal motility is linked to an elongated cell 
shape. Cells are polarised with an obvious leading edge. Interactions with the 
extra-cellular matrix (ECM) are regulated by integrins and ECM-degrading 
proteolytical enzymes are required generating the path for migration. In 
contrast, amoeboid migration is linked to a characteristic round shape of the 
cells. Amoeboid cell migration is independent of ECM degradation and cells are 
able to squeeze through gaps in ECM fibres. Some cell types can use both modes 
of invasiveness and undergo transitions between them. Changes between modes 
of invasion rely on the specifics of the microenvironment.  
1.3.2 Actin-based cell migration 
Cell migration is dependent on specific functions of the actin cytoskeleton. Actin 
is a nucleotide-binding protein that is found at high intracellular concentrations 
and is highly conserved between species [99]. The actin cytoskeleton is crucial 
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for cell shape, stability and internal transport. G-actin molecules, the 
monomeric form of the protein, are the building blocks for filaments (F-actin) 
and the actin network. Rearrangement of this actin cytoskeleton is the basis of 
actin-based motility. Actin-based motility can be classified into the following 
steps: protrusion, adhesion, retraction and de-adhesion [100, 101]. During 
protrusion parts of the cell spread out into new areas and new contacts with 
surrounding areas are built during adhesion. During retraction the cell body is 
shifted in the direction of the movement followed by loss of contact to 
surrounding areas (de-adhesion). These processes have to be regulated tightly 
for efficient cell migration.  
 
 
 
Figure 1.5: The structures of an actin monomer and actin filament  
(A) The actin monomer has a nucleotide (either ATP or ADP) bound in a deep cleft in the 
center of the molecule. (B) Arrangement of monomers in a filament. Although the filament is 
often described as a single helix of monomers, it can also be thought of as consisting of 
two protofilaments, held together by lateral contacts, which wind around each other as two 
parallel strands of a helix, with a twist repeating every 37 nm. All the subunits within the 
filament have the same orientation. (C) Electron micrographs of negatively stained actin 
filaments. (C, courtesy of Roger Craig.) [102] 
 
To build up actin filaments from monomers oligomers must be formed first. As 
actin dimers and trimers are not a stable entity spontaneous assembly of G-actin 
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into oligomers is not favoured. A nucleation step is needed for this rate-limiting 
step in the formation of filaments. Different actin nucleators facilitate the 
formation of actin oligomers. Elongation of these newly formed oligomers is 
directly dependent on the monomer concentration. Actin monomers consist of 4 
structural domains and an ATP binding cleft in the middle. As shown in Figure 
1.5 each actin monomer has two distinguishable sites, a plus and a minus end. 
Actin filaments are organised into double helical polymers of globular subunits 
arranged head to tail leading to molecular polarity of these filaments.  
Actin monomers are added to the (+) end of the filament in an ATP-bound state 
and released from the (-) end in an ADP-bound state as polymerisation is 
accompanied by hydrolysis of ATP to ADP+Pi and the subsequent release of the -
phosphate group. The biochemical differences of ATP bound actin on one end of 
the filament and ADP bound actin at the other end are crucial for directed 
polymerisation. The ability to polymerise depends on the concentration of actin 
monomers. The minimal required concentration of G-actin to drive 
polymerisation is the critical concentration. Due to the hydrolysis of ATP to ADP 
within the filament the critical concentration is different between the (+) and 
the (-) end of the filament leading to higher affinity for ATP-bound actin to the 
(+) end. As the intracellular concentration ATP-bound actin lies between the 
critical concentration of the (+) and the (-) end of the filament addition of 
monomers to the (+) end and depolymerisation at the (-) end is favoured, a 
process called treadmilling. 
In a steady state the overall length of filaments does not change which means 
that the rates of polymerisation and depolymerisation are equal. Without 
regulatory proteins treadmilling is slow. More and more regulatory proteins are 
being discovered leading to the appreciation of the complexity of the 
intracellular actin machinery. Several core proteins that increase treadmilling 
were identified: profilin, ADF/cofilin, capping protein (CP), Arp2/3 complex and 
activators of the Arp2/3 complex (Figure 1.6). 
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Figure 1.6: Dendritic Nucleation/Array Treadmilling Model for Protrusion of the Leading 
Edge 
(1) Extracellular signals activate receptors. (2) The associated signal transduction pathways 
produce active Rho-family GTPases and PIP2 that (3) activate WASp/Scar proteins. (4) 
WASp/Scar proteins bring together Arp2/3 complex and an actin monomer on the side of a 
pre-existing filament to form a branch. (5) Rapid growth at the (+) end of the new branch (6) 
pushes the membrane forward. (7) Capping protein terminates growth within a second or 
two. (8) Filaments age by hydrolysis of ATP bound to each actin subunit (white subunits 
turn yellow) followed by dissociation of the _ phosphate (subunits turn red). (9) ADF/cofilin 
promotes phosphate dissociation, severs ADP-actin filaments and promotes dissociation of 
ADP-actin from filament ends. (10) Profilin catalyzes the exchange of ADP for ATP (turning 
the subunits white), returning subunits to (11) the pool of ATP-actin bound to profilin, ready 
to elongate (+) ends as they become available. (12) Rho-family GTPases also activate PAK 
and LIM kinase, which phosphorylates ADF/cofilin. This tends to slow down the turnover of 
the filaments. (Redrawn from a figure in Pollard et al., 2000). Reprinted with permission from 
the Annual Review of Biophysics and Biomolecular Structure, Volume 29, copyright 2000 by 
Annual Reviews, www.annualreviews.org. [100] 
 
In a simplified view a pool of unpolymerised actin monomers is important for a 
quick reaction to external stimuli (for reviews: [100, 103]). A high G-actin 
concentration allows faster growth of the free actin filaments. Free monomeric 
actin is mostly bound to profilin or actin sequestering proteins such as thymosin-
4. Actin monomers bound to profilin are ready for addition to filaments 
whereas monomers bound to thymosin-4 are placed into reserve. Profilin binds 
to the plus end of the monomer inhibiting spontaneous nucleation and blocking 
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binding to the (-) end of filaments but ready for addition to a free (+) end. The 
binding of actin to profilin induces a nucleotide exchange from ADP to ATP 
whereas thymosin-4 slows down the rate of spontaneous ATP hydrolysis. Binding 
of actin monomers to the (+) end of the filament induces a conformational 
change in actin reducing its affinity for profilin. Thymosin-4 competes with 
profilin for binding of actin monomers but profilin has a stronger affinity for 
monomers. Formation of new filaments is induced by external stimuli. These 
extracellular signals activate members of the WASp/Scar family which in turn 
stimulate the Arp2/3 complex. Members of the Wiskott-Aldrich syndrome protein 
(WASP) family are nucleation promoting factors, capable of activating Arp2/3. 
The Arp2/3 complex is a multiprotein complex of actin related proteins serving 
as a nucleation factor for actin polymerisation and as (-) end of new filaments. It 
initiates the formation of new daughter filaments on the side of existing 
filaments. The Arp2/3 complex is intrinsically inactive and needs to be 
activated. A stable nucleus for further actin polymerisation is formed when two 
subunits of the Arp2/3 complex mimicking actin monomers bind one additional 
actin monomer. New filaments are polymerised rapidly until they are capped by 
the capping protein (CP), preventing further monomer addition. ATP hydrolysis 
within the filament and the subsequent dissociation of the -phosphate 
determines the age of the filament and older, ADP-containing parts are favoured 
to bind ADF/cofilin. Treadmilling is normally limited by the slow dissociation 
rate of actin monomers from the (-) end of the filament however ADF/cofilin can 
increase the rate of actin filament by different means. Binding of ADF/cofilin 
changes the twist of the actin helix inducing a mechanical stress that weakens 
the contacts between actin subunits in the filaments. This facilitates the 
dissociation of ADP-actin subunits from the (-) end of the filaments. Binding of 
ADF/cofilin also induces debranching and severing of the filaments into short 
segments. Severing is important to increase the concentration of free filament 
ends and therefore disassembly. Once ADP-bound monomers are released into 
the cytoplasm profilin competes with ADF/cofilin for binding and subsequently 
induces a nucleotide exchange, converting monomers back to ATP-actin/profilin. 
This complex is then ready to be added to new (+) ends. Capping of (+) ends as 
well as rapid depolymerisation of (-) ends is important to control the 
concentration of free actin monomers ready for polymerisation. Capping a large 
fraction of actin filament (+) ends limits the length of filaments and inhibits non-
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productive consumption of monomers. Capping protein can be regulated by 
phoshatidyl-inositol-4,5-bisphosphate (PIP2) which is not only able to inhibit the 
function of CP but also to uncap (+) ends. 
1.3.3 Higher order actin oganisation and its regulation 
Actin filaments can assemble in different higher order patterns within the cell. 
Different protrusive structures with dense arrays of actin filaments have been 
described [103-105]. The simplest ones are filopodia, finger-like protrusions 
containing tight bundles of actin filaments held together by cross-linking 
proteins with their (+) ends facing the membrane. Lamellipodia are protrusive 
sheets with a ruffling appearance, containing branched actin filaments. These 
structures can co-exist at the leading edge. A loose actin meshwork is found in 
the cell body with apparently randomly organised actin filaments. Within the 
cell body stress fibres can form [106, 107]. Stress fibres are contractile acto-
myosin structures found in non-muscle cells, which are arranged in bundles of 
alternating polarity interspersed with bipolar myosin II filaments and crosslinked 
with actin-binding proteins such as -actinin. Association of stress fibres and 
focal adhesions prevent retraction at the rear of the cell and therefore cell 
migration. Three categories of stress fibres are found in mammalian cells: 
ventral stress fibres that are attached to focal adhesions at both ends, dorsal 
stress fibres that are attached to focal adhesion on one end and traverse arcs of 
curved bundles that do not associate with focal adhesions. It is currently 
accepted that an optimal G- to F-actin ratio in the cell is required for efficient 
cell motility as efficient cell movement requires actin polymerisation, but high 
levels of stress fibres can oppose cell migration by increasing cell adhesion. 
Several external signals can induce rearrangement of the actin cytoskeleton. 
Signalling pathways seem to converge on Cdc42, Rac and Rho, members of the 
Rho-family of GTPases. GTPases act as molecular switches controlling cellular 
processes by cycling between an active, GTP-bound state and an inactive, GDP-
bound state. Activation of each of these Rho-GTPases has profound effects on 
the actin cytoskeleton (Figure 1.7) [101]. 
Chapter 1, Introduction   30 
 
 
Figure 1.7: The dramatic effects of Rac, Rho, and Cdc42 on actin organisation in fibroblasts  
In each case, the actin filaments have been labelled with fluorescent phalloidin, and focal 
contacts have been located with an antibody against vinculin. (A) Serum-starved fibroblasts 
have actin filaments primarily in the cortex, and relatively few focal contacts. (B) 
Microinjection of a constitutively activated form of Rho causes the rapid assembly of many 
prominent stress fibers and focal contacts. (C) Microinjection of a constitutively activated 
form of Rac, a closely related monomeric GTPase, causes the formation of an enormous 
lamellipodium that extends from the entire circumference of the cell. (D) Microinjection of a 
constitutively activated form of Cdc42, another Rho family member, causes the protrusion 
of many long filopodia at the cell periphery that form adhesive contacts with the 
substratum. The distinct global effects of these three GTPases on the organisation of the 
actin cytoskeleton are mediated by the actions of dozens of other protein molecules that are 
regulated by the GTPases. Many of these target proteins resemble the various actin-
associated proteins that we have discussed in this chapter. [108] 
 
RhoA promotes the formation of actin stress fibres and focal contacts through 
phosphorylation of myosin light chain (MLC) and inactivation of the myosin light 
chain phosphatase. Phosphorylated MLC assembles into filaments and associates 
with actin filaments to form contractile stress fibres. Rac causes formation of a 
large lammellipodia and actin ruffles whereas Cdc42 stimulates the formation of 
filopodia. These effects are mediated by the action of downstream effectors, 
some of them described in section 1.3.2. These proteins are not only involved in 
intracellular signalling but can also determine the mode of cell invasion. 
Mesenchymal motility is mainly driven by Rac and Cdc42 whereas amoeboid 
migration is linked to a RhoA signalling. 
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1.3.4 Actin isoforms 
Three actin isoforms were identified in vertebrates: -, -and -actin, which are 
mostly localised in the cytoplasm. -actins are mostly found in muscle cells, - 
and -isoforms in non-muscle cells. - and -actin isoforms vary in only four 
amino acids in their N-termini and are co-expressed in most tissues although the 
-isoform is expressed in excess [109]. - and -actin seem to have distinct 
functions in the cell however these are not quite clear. Spatial segregation has 
been observed for the - and -isoforms. -actin is the main isoform to drive 
protrusion whereas -actin displays a more ubiquitous distribution, often found 
in perinuclear regions and often incorporated into stress fibres. Enrichment of -
actin to the leading edge may be achieved by preferred interaction with certain 
actin binding proteins and in part by localisation of its mRNA and its local 
translation. All actin isoforms are mostly found in the cytoplasm however actin 
has also been implicated to localise in the nucleus and to play a role in 
chromatin remodelling, RNA processing, transcription and nucleocytoplasmic 
transport [110-112]. However the molecular mechanisms by which actin exerts 
these functions as well as the polymerisation status of nuclear actin remain 
unclear [113]. 
 
1.4 Hypoxia and glucose metabolism 
A hallmark of hypoxic tumours is their shift from aerobic to anaerobic 
metabolism marked by an increase in the rate of glycolysis and lactate 
production [102]. Glycolysis is the step by step breakdown of one molecule of 
glucose (consisting of 6 carbon atoms) broken down into two molecules of 
pyruvate (each containing three carbon atoms). During this process the binding 
energy of glucose is conserved as metabolic energy in form of ATP molecules. 
Hypoxic tumours rely on glycolysis followed by lactic acid fermentation as main 
source of ATP/energy as oxidative phosphorylation is restricted as an energy 
source due to the lack of oxygen. Metabolic enzymes, such as L-lactate 
dehydrogenase and fructose-bisphosphate aldolase are upregulated in a HIF-
dependent manner making glycolysis in hypoxic tumours more efficient.  
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Figure 1.8: Overview over the reaction involved in glycolysis [102] 
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Figure 1.8 shows an overview over the glycolytic pathway including the reactions 
that are catalysed by fructose-bisphosphate aldolase and triosephosphate 
isomerase. Aldolase is the enzyme that catalyses the reaction of cleaving 
fructose 1,6-bisphosphate into glyceraldehyde 3-phosphate and 
dihydroxyacetone phosphate, a six-carbon molecule split into two three-carbon 
molecules. This reaction is reversible in intracellular conditions. The subsequent 
reaction in the glycolytic pathway is catalysed by triosephosphate isomerase. 
Glyceraldehyde 3-phosphate and dihydroxyacetone phosphate are isomers that 
are converted into one another by triose phosphate isomerase. This reaction is 
reversible but as glyceraldehyde 3-phosphate is removed by subsequent 
reactions of glycolysis, the reaction tends to produce glyceraldehyde 3-
phosphate. By the subsequent reactions of aldolase and triose phosphate 
isomerase two molecules of glyceraldehyde 3-phosphate are formed from one 
molecule of fructose 1,6-bisphosphate funneling dihydroxyacetone phosphate 
into the main glycolytic pathway. 
 
 
 
Figure 1.9: Reaction catalysed by lactate dehydrogenase 
 
In the absence of oxygen lactate is formed from the end product of glycolysis, 
namely pyruvate (Figure 1.9). Lactate dehydrogenase catalyses the reduction of 
pyruvate to form lactate. This reaction is necessary to regenerate redox balance 
to keep glycolysis running under hypoxic conditions. 
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1.5 Quantitative proteomics (SILAC) 
With proteomic techniques large numbers of proteins can be analysed, however 
so far results have mostly been qualitative. In recent years several methods have 
been established to obtain quantitative information [114]. Mass spectrometric 
analyses are not quantitative per se so quantitative data is mostly obtained by 
reporting relative changes in protein amounts between two samples. To be able 
to compare two samples to each other they have to be labelled. Labelling can be 
introduced at different stages of the workflow with various labelling techniques, 
using different chemical or metabolic labelling methods. To differentiate 
between labelled and unlabelled peptides in mass spectra a mass difference of 
at least 3 Da is favourable. A quantitative approach using metabolic labelling has 
emerged in recent year. Stable isotope labelling by amino acids in cell culture 
(SILAC) was first described in 2002 [115]. Metabolic labelling is a non-radioactive 
approach that substitutes specific standard essential amino acids in the growth 
medium with an isotopically labelled form of that amino acid so they are 
incorporated into cellular proteins. Labelling of different essential amino acids 
with 13C, 15N or 2H has been described in the literature [116]. SILAC is a 
straightforward approach that induces a mass shift between peptides pairs in 
labelled and unlabelled samples but no other chemical changes, so labelled 
peptides behave the same as their non-labelled counterparts. Cultures are grown 
for at least 5 doubling times to achieve 100% incorporation of labelled amino 
acids, including proteins with low turnover. Complete labelling of proteins is 
important as incomplete labelling makes it difficult to obtain reliable relative 
comparison. SILAC is a good tool to investigate protein-protein interactions. 
Often protein interactions are transient, show high background interactions and 
false-positives in non-quantitative mass spectrometric approaches. It is often a 
trade-off between sensitivity and specificity. In SILAC however background 
proteins bind equally leading to a one-to-one ratio between labelled and 
unlabelled peptides, whereas specific interactions show differential ratios, 
removing false positive results. There are a few advantages of SILAC labelling 
over other labelling techniques: less manipulation steps are required in the 
workflow so limited material can be analysed. The fragmentation patterns of 
peptides are identical apart from the mass shift.  
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Furthermore, several peptides from the same protein can be compared, leading 
to a higher confidence level for ratios identified. However, it has to be kept in 
mind that peptides are analysed stochastically by the mass spectrometer which 
means analysis of high abundant proteins is favoured over co-eluting low 
abundant proteins. Other factors such as accessibility of the protease, solubility 
of the peptide as well as its ionisation efficiency are important for peptide 
identification. Identification of single peptides can lead to false positive 
identification, if they do not show a high sequence score whereas identification 
of several peptides (ideally covering a wider protein sequence) can give a more 
reliable ratio. In this study SILAC is used to identify new interaction partners of 
PHDs. 
 
1.6 Aims 
In this project PHDs were investigated to gain a better understanding of 
intracellular oxygen sensing. As discussed in section 1.2.1.4, each PHD isoform 
was found to be involved in various different pathways however their substrates 
are mostly unknown. The aim of this project is to identify new substrates that 
contribute to PHD-dependent functions. A quantitative proteomic approach was 
used to identify proteins that interact with PHDs. After identifying potential new 
substrates, their hydroxylation status was investigated to identify new 
substrates. Furthermore, the biological function of the identified interaction was 
investigated in more detail. 
 
  
 
 
 
 
 
 
 
Chapter 2 – Material and methods 
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2 Material and methods 
2.1 Materials 
2.1.1 General reagents 
Unless listed in Table 2.1, reagents were purchased from Sigma. 
Table 2.1: General reagents and kits 
Reagent Company 
Acrylamide solution – 30% acrylamide, 37.5:1 
bis-acrylamide 
Severn Biotech Ltd. 
Ammonium persulfate (APS) Fisher Scientific 
BSA standard (2 mg/ml) Pierce 
DH5 competent cells Invitrogen 
DMEM Invitrogen 
Dynabeads M-280 sheep anti-mouse IgG Invitrogen 
Rapid DNA ligation kit Roche Applied Sciences 
ECL Western Blotting Detection reagent GE Healthcare Life Sciences 
Ethanol Fisher Scientific 
FBS Autogen Bioclear, Harlan 
Gel extraction kit Qiagen 
L-glutamine Invitrogen 
Glycine Fisher Scientific 
HyperLadderI DNA marker Bioline 
-ketoglutarate (TKG) Synthesised as described by 
MacKenzie [35] 
KCl Fisher Scientific 
Laemmli sample buffer 2x Biorad 
Lipofectamine 2000 transfection reagent Invitrogen 
MgCl2 Fisher Scientific 
Methanol Fisher Scientific 
NaCl Fisher Scientific 
Nitrocellulose membrane 0.22m Anachem 
PCR purification kit Qiagen 
Plasmid purification kit Qiagen 
QuickChange Site-directed Mutagenesis Kit Stratagene 
High-Range molecular weight marker (protein) 
(RPN 800E) 
GE Healthcare Life Sciences 
Restriction enzymes Roche Applied Sciences 
RPMI Invitrogen 
SimplyBlue Safe Stain (Coomassie) Invitrogen 
SDS (sodium dodecyl sulphate) Fisher Scientific 
Tris base ultrapure Melford 
Trypsin Invitrogen 
Vectrashield mounting medium Vector laboratories Inc. 
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Biorad agarose gel casters, agarose gel tanks, Mini-Protean III Ready Gel 
System for SDS-PAGE and Western blotting 
Invitrogen Novex mini-cell gel tank and NuPage 10% Bis-Tris gels 
Biotrace Invivo2 Hypoxic chamber and Ruskinn gas mixer 
Tissue culture reagents Becton Dickson 
 
2.1.2 General buffers and solutions 
Table 2.2: General buffers and solution 
 
Solution 
 
Composition 
L-Broth (LB) medium 10 g/l Tryptone 
5 g/l yeast extract 
10 g/l mM NaCl 
LB agar plates LB medium + 15 g/l bacto agar 
Tris-acetate-EDTA (TAE) 40 mM Tris-acetate, 1 mM EDTA 
Phosphate buffered saline (PBS) 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4, pH 7.4 
PBS-T PBS + 0.05% Tween-20 
1x SDS-PAGE running buffer 25 mM Tris 
192 mM glycine 
0.1% SDS, pH 8.3 
1x blotting buffer 25 mM Tris 
192 mM glycine 
0.01% SDS 
20% methanol 
Blocking buffer for Western blots 5% milk powder in PBS-T 
Stripping buffer for Western blots 0.2 M glycine 
1% SDS 
pH 2.5 
RIPA 50 mM Tris-HCl 
150 mM NaCl 
2 mM EDTA 
1% NP-40 
0.5% sodium deoxycholate 
0.1% SDS 
NP-40 lysis buffer (TNN) 50 mM Tris-HCl pH 7.5 
150 mM NaCl 
5 mM EDTA 
0.5% NP-40 
protease inhibitor cocktail 
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Washing buffer for IP 50 mM Tris-HCl pH 7.5 
150 mM NaCl 
5 mM EDTA 
0.25% NP-40 
Lysis buffer for actin quantification 20 mM KPO4 pH 8 
10 mM Pipes pH 8 
5 mM EGTA pH 8 
2 mM MgCl2 
0.1% TritonX-100 
3.7% formalin 
2 M Phalloidin-TRITC 
Washing buffer for actin quantification 0.1% Saponin 
20 mM KPO4 pH 8 
10 mM Pipes pH 8 
5 mM EGTA pH 8 
2 mM MgCl2 
 
2.2 Methods 
2.2.1 DNA techniques 
2.2.1.1 Cloning of PHD-FLAG plasmids 
To subclone PHD1 or PHD3 into a pCMV-5a vector (Sigma) containing a C-
terminal FLAG-tag the following cDNA plasmids were purchased from Invitrogen: 
IOH13327 containing the cDNA sequence for PHD3 and IOH27186 containing the 
cDNA sequence for PHD1. A PCR using the primers specified in Table 2.4 was 
used to introduce HindIII and BamHI or EcoRI and HindIII restriction sites 
adjacent to the PHD1 or PHD3 coding sequence respectively. The PCR was 
performed using a BioMix mastermix with 2 µM of each primer and 110 ng 
template for PHD1 or 130 ng template for PHD3 under the following conditions: 
Table 2.3: PCR conditions 
Cycles Temperature  Time 
1 94°C 2 minutes 
35 94°C 30 seconds 
 55°C 40 seconds 
 72°C 3 minutes 
 
The PCR products were run on a 1% agarose gel, the appropriate band was cut 
out and purified from the gel using QIAquick gel extraction kit (Qiagen). Then 30 
µl of the purified PCR products as well as 2 µg of the vector pFLAG-CMV-5a were 
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digested first with BamHI (Roche) for PHD1 or HindIII (Invitrogen) for PHD3 for 4 
hours at 37°C. After a purification step a second digest was set up overnight at 
37°C with HindIII for PHD1 or EcoRI (Invitrogen) for PHD3. Afterwards the 
digested insert was purified again. The digested vector was dephosphorylated 
using shrimp alkaline phosphatase (Promega) according to the manufacturer’s 
instructions.  
Ligations were carried out using Rapid DNA ligation kit (Roche). An approximate 
3 fold molar excess of the insert fragment over the vector fragment was used for 
the ligation reaction. The reaction was incubated at room temperature for 2 
hours before 5 µl of the ligation mix were transformed into DH5α bacteria. 
Clones containing the insert were sequenced (Research services, Beatson 
Institute) to confirm the correct formation of the fusion protein. 
The PHD2-Myc/FLAG plasmid was purchased from Origene. Myc-tagged triple 
mutant HIF1 (HIF1TM) and HIF2 (HIF2TM) constructs were a kind gift from 
M.C. Simon [117]. 
Table 2.4: Primer sequences 
Name Experiment Sequence 5’-3’ 
PHD1 forward Cloning of PHD1-
FLAG 
GCCAAGCTTGCCGCCATGGACAGCCCGTGCCAGCCG 
PHD1 reverse Cloning of PHD1-
FLAG 
GCCGGATCCGGTGGGCGTAGGCGGCTGTGAT 
PHD3 forward Cloning of PHD3-
FLAG 
GCCGAATTCGCCGCCATGCCCCTGGGACACATCATG 
PHD3 reverse Cloning of PHD3-
FLAG 
GCCAAGCTTGTCTTCAGTGAGGGCAGATTC 
Actin P70A 
forward 
Site directed 
mutagenesis of 
GFP-actin 
CTCACCCTGAAGTACGCCATCGAGCACGGC 
Actin P70A 
reverse 
Site directed 
mutagenesis of 
GFP-actin 
GCCGTGCTCGATGGCGTACTTCAGGGTGAG 
Actin P322A 
forward 
Site directed 
mutagenesis of 
GFP-actin 
CACTGCCCTGGCAGCCAGCACAATGAAG 
Actin P322A 
reverse 
Site directed 
mutagenesis of 
GFP-actin 
CTTCATTGTGCTGGCTGCCAGGGCAGTG 
 
 
All primers were purchased from Eurofins MWG. 
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2.2.1.2 Site directed mutagenesis 
The pEGFP-β-actin plasmid was purchased from Clontech. Point mutations were 
introduced into the plasmid using the site-directed mutagenesis kit from 
Stratagene following the manufacturer’s instructions. Primers were designed 
including the desired mutation (listed in Table 2.4). A 50 µl reaction was set up 
containing 25 ng plasmid DNA, 125 ng of each primer, 1 µl dNTP mix, 5 µl 10x 
reaction buffer and 1 µl PfuTurbo DNA polymerase. A PCR program with the 
following parameters was used: 
Cycles Temperature  Time 
1 95°C 3 minutes 
16 95°C 90 seconds 
 55°C 1 minute 
 68°C 12 minutes 
 
The parental DNA was digested by adding the restriction enzyme DpnI (10U/µl) 
to the reaction mix and incubating the mixture for 2 hours at 37°C. 5 µl of the 
reaction was transformed into competent DH5α cells (see section 2.2.1.3). 
Sequences were verified by sequencing (Research services, Beatson Institute for 
Cancer Research). 
2.2.1.3 Transformation of DH5 bacteria 
50 l DH5α competent cells were thawed on ice. 5 µl DNA was added and cells 
were incubated on ice for 15-30 minutes. After a heat shock of 40 seconds at 
42°C cells were incubated on ice for further 2 minutes. 250-500 µl LB medium 
were added and cells were incubated for 30 minutes at 37°C shaking at 220 rpm. 
Cells were then plated onto agar plates containing the relevant antibiotic and 
grown overnight at 37°C. Single colonies were inoculated in LB medium 
containing the relevant antibiotic and grown overnight at 37°C for DNA 
purification. Small scale or large scale plasmid DNA preparations were 
performed using Qiagen kits following the manufacturer’s instructions. 
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2.2.1.4 Agarose gel 
1% (w/v) agarose was boiled in 1x TAE buffer. Before solidification 1 µg/ µl 
ethidiumbromide was added and the gel was allowed to solidify in the gel 
chamber. DNA samples were diluted in 10x loading buffer containing glycerol 
and bromphenol blue. Samples were then separated at 100V in 1x TAE running 
buffer. DNA was visualised by a UV transilluminator. Specific bands could be cut 
out and extracted from the gel using the Qiagen gel extraction kit according to 
the manufacturer’s instructions. 
2.2.2 Cell lines and growth conditions 
The human colon carcinoma cell line HCT116 was cultured in RPMI medium 
(Invitrogen) supplemented with 10% FBS (Harlan) and 2 mM L-glutamine 
(Invitrogen). The serum was heat-inactivated at 55°C for 45 minutes prior to 
use. The renal clear cell carcinoma cell line RCC4, the melanoma cell line A375 
and the osteosarcoma cell line U2OS were cultured in DMEM medium (Invitrogen) 
supplemented with 10% FBS and 2 mM L-glutamine. Cells were maintained in a 
humidified incubator at 37°C in 5% CO2. For routine culturing cells were 
incubated with trypsin solution (0.25% Trypsin in PBS-EDTA) and then plated at a 
density as needed for culturing or transfection.  
For the SILAC screen the SILACTM Protein Identification (ID) and Quantitation Kit 
from Invitrogen was used (Catalog No.: MS10031 using RPMI-Flex plus 13C6-
labelled arginine: Catalog No.: MS10011). Cells were grown in heavy and light 
medium until 100% incorporation of labelled amino acids was achieved. 
2.2.3 Freezing and thawing of cells 
Cells were harvested and re-suspended in 90% FCS supplemented with 10% DMSO. 
Cells were frozen overnight at -80°C in a cryo freezing container (Nalgen) before 
they were placed in a liquid nitrogen tank. When taken out of the nitrogen tank 
cells were thawed rapidly at 37°C. Cells were added to pre-warmed medium, 
then were centrifuged at 1000 rpm for 4 minutes to remove the DMSO and finally 
re-suspended in fresh medium for culturing. All cells were regularly tested for 
mycoplasma contamination (Research Services, Beatson Institute). 
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2.2.4 Transfection using lipofectamine 2000 
Cells were transfected with Lipofectamine 2000 transfection reagent (Invitrogen) 
according to manufacturer’s instructions. Cells were plated the day before 
transfection to allow them to adhere overnight. 4-5 hours after the transfection 
mix was added to the cells the medium was replaced with fresh medium. 
Depending on the assay cells were analysed 24-48 hours after transfection. The 
following constructs were used for the knock down of specific genes: 
Table 2.5: RNA interference and oligonucleotide sequences 
Name Target 
gene 
Sense sequence Company 
shPHD1 
(22327) 
PHD1 CCGGACTGGGACGTTAAGGTGCATG 
CTCGAG CATGCACCTTAACGTCCCAGTTTTTT 
OpenBiosystems 
shPHD2 
(1043) 
PHD2 CCGGGACGACCTGATACGCCACTGT 
CTCGAG ACAGTGGCGTATCAGGTCGTCTTTTT 
OpenBiosystems 
shPHD3 
(1048) 
PHD3 CCGGCACCTGCATCTACTATCTGAA 
CTCGAGTTCAGATAGTAGATGCAGGTGTTTTT 
OpenBiosystems 
shControl  CCTAAGGTTAAGTCGCCCTCG CTCGAG 
CGAGGGCGACTTAACCTTAGG 
Addgene 
    
siActin (5) actin CUAUGACUUAGUUGCGUUAdTdT Sigma 
siActin (7) actin CCUGUACACUGACUUGAGAdTdT Sigma 
Non-
targeting 
siRNA pool 
 Pool of non-targeting siRNAs Dharmacon 
 
The generation of A375 stable knockdown cell lines was described previously by 
[118]. 
2.2.5 Drugs and treatment of cells with these drugs 
After transfection cells were incubated for 24 hours before they were subjected 
to either normoxia (21% oxygen) or hypoxia (1% oxygen) for another 24 hours. 
Hypoxia was achieved using a humidified Invivo2 500 hypoxic chamber (Biotrace, 
Bridgend, UK) and Ruskin hypoxic gas mixer at 37°C with 1% O2, 5% CO2 and 94% 
N2 unless otherwise specified. Hypoxia was defined as 24 hours to equilibrate the 
sample including all buffers and plastic dishes to hypoxic conditions. Normoxic 
cells could then be treated for 3 hours with 1 mM Dimethyloxaloylglycine 
(DMOG), a non-cleavable α-ketoglutarate analog, whereas hypoxic cells could be 
treated for 1 hour with 1mM α-ketoglutarate trifluoromethyl benzyl ester 
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(TαKG), a cell-permeable α-ketoglutarate derivative which can re-activate prolyl 
hydroxylases under hypoxia. 
The actin drugs Latrunculin A (Sigma) and Cytochalasin D (Sigma) were used to 
disrupt the actin cytoskeleton. Latrunculins are toxins isolated from the red sea 
sponge Negombata magnifica. Latrunculin binds to actin monomers in a 1:1 
stoichiometry so they are unable to polymerise [119, 120]. Cytochalasins are 
extracted from zygosporin mansonii. They bind to the (+) end of actin filaments 
and prevent monomer addition [121]. This leads to depolymerisation of actin 
filaments by cellular mechanisms. Cells were treated with 300 nM Latrunculin A 
or 10µg/ml Cytochalasin D for 15 minutes. 
2.2.6 Preparation of lysates 
Treated or untreated cells were washed twice with cold PBS (on ice) and lysed in 
RIPA or TNN buffer containing protease inhibitors (Sigma). Hypoxic cells were 
lysed in hypoxic RIPA or TNN buffer in the hypoxic chamber. Cells were taken 
out of the hypoxic chamber after lysis and placed on ice immediately. Cell 
extracts were incubated on ice for 20 minutes before they were centrifuged at 
12,000 x g for 10 minutes at 4°C to remove debris. Supernatants were 
transferred to fresh tubes. The protein concentration of cell extracts was 
measured by using Bradford reagent (Sigma) according to the manufacturer’s 
instructions. BSA dilutions ranging from 0.08 mg/ml up to 2 mg/ml were used as 
standards. 10 µl of the standards as well as of a 1:10 dilution of the cell extracts 
were analysed in a 96well plate by adding 200 µl Bradford reagent. After an 
incubation of 5 minutes the plate was analysed at 595 nm using a Spectra Max 
plus plate reader (Molecular devices). 
2.2.7 SDS-PAGE 
Proteins samples were resolved on SDS-PAGE. Denaturing polyacrylamide gels of 
10% or 12% acrylamide were cast using a mini-Protean gel caster (Biorad). Gels 
were overlaid with water and allowed to set until polymerised. Excess water was 
removed and a 5% stacking gel was poured on top of the resolving gel. Protein 
samples were loaded onto the gel with a prestained protein marker next to them 
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(GE Healthcare) and run in 1x SDS-PAGE running buffer through the stacking gel 
at 80 V before separating the samples at 120 V. 
Protein samples used for proteomics were run on 10% precast NuPage gels 
(Invitrogen) in 1x MOPS SDS running buffer at 150 V. Proteins on NuPage gels 
were visualised by Coomassie staining. The staining was carried out according to 
manufacturer’s instructions. 
2.2.8 Immunoblotting 
After electrophoresis proteins were transferred from the gel onto a 
nitrocellulose membrane (0.22 µm, Anachem) in 1x SDS-PAGE blotting buffer 
using a wet transfer system (Biorad). Proteins were transferred at 200 mA per 
gel for 2 hours in ice cold buffer. The membrane was blocked in 5% milk (Marvel) 
in PBS-T for non-specific binding at room temperature for 30-60 minutes. Then 
the membrane was washed in PBS-T and incubated with the primary antibody for 
2 hours at room temperature or over night at 4°C (for antibody dilutions see 
Table 2.6). Following 3 washes in PBS-T for 5-10 minutes, the blots were 
incubated with the appropriate horseradish peroxidase-conjugated secondary 
antibody at room temperature for 30-60 minutes (for antibody-dilutions see 
Table 2.7). After 3 more washes with PBS-T for 5-10 minutes proteins were 
visualized by Enhanced Chemiluminescent Reagents (ECL, GE Healthcare) and 
exposure to Fuji X-Ray films.  
To reprobe the membrane with another primary antibody, membranes were 
incubated in stripping buffer for 20-30 minutes at room temperature, followed 
by blocking them again in 5% milk in PBS-T and incubation with a new primary 
antibody. 
Table 2.6: Antisera 
Antibody Company Type Dilution 
Actin (AC-40) Sigma Mouse monoclonal 1:5000 
Aldolase Abcam Mouse monoclonal 1:500 
Aldolase Abcam Goat polyclonal 1:2000 
HIF1 BD Bioscience Mouse monoclonal 1:500 
FLAG (M2) Sigma Mouse monoclonal 1:5000 
GFP Clontech Mouse monoclonal 1:2000 
LDH Abcam Mouse monoclonal 1:4000 
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LDH Abcam Goat polyclonal 1:2000 
myc Cell Signalling Mouse monoclonal 1:1000 
PHD1 Novus Rabbit polyclonal 1:2000 
PHD2 Kind gift by Kevin 
Gattner 
Mouse monoclonal 1:200 
PHD3 Kind gift by Kevin 
Gattner 
Mouse monoclonal 1:50 
Triosephosphate 
isomerase 
Abcam Mouse monoclonal 1:500 
Triosephosphate 
isomerase 
Abcam Goat polyclonal 1:5000 
Tubulin Sigma Mouse monoclonal 1:2000 
    
Immunostaining    
FLAG-Cy3 Sigma Mouse monoclonal 1:100 
FLAG-FITC Sigma Mouse monoclonal 1:100 
DNAseI-Alexa488 Invitrogen 100 µg/ml 1:50 
Phalloidin-TRITC Sigma 1 mg/ml 1:200  
Table 2.7: Secondary antibodies 
Secondary 
antibodies 
Company Dilution 
Anti-mouse IgG, 
HRP-linked 
Cell Signalling 
 
1:5000 
Anti-rabbit IgG, 
HRP-linked 
Cell Signalling 1:5000 
Anti-goat IgG, 
HRP-linked 
Cell Signalling 1:5000 
 
2.2.9 Immunoprecipitations 
2.2.9.1 Dynabeads 
24 hours before transfection cells were plated onto 10 cm tissue culture dishes. 
Cells were transfected with 4 µg DNA (FLAG-tagged PHD plasmids) using 
Lipofectamine 2000 transfection reagent. After 24 hours cells were treated 
appropriately (as described in section 2.2.5). After the treatment cells were 
washed twice in ice cold PBS and lysed in 1 ml cold TNN lysis buffer as described 
in section 2.2.6. 5% of the total lysate was kept for Western blot analysis.  
1-2 mg of total protein was used for each immunoprecipitation. 
Immunoprecipitations were performed by adding 1 µg of the appropriate 
antibody (0.2 µl of FLAG-M2 antibody) to the lysate for 2-3 hours at 4°C. In the 
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meantime 20 µl of Dynabeads- M280 sheep anti mouse IgG slurry (Invitrogen) was 
washed once with 1%BSA/PBS to block unspecific binding and once with TNN lysis 
buffer. The washed beads were then added to the lysate containing antibodies 
and the sample was incubated for 1 hour at 4°C. Afterwards the beads were 
washed twice in washing buffer. The dry beads were resuspended in 50 µl 1x 
Laemmli sample buffer and boiled at 95°C for 5-10 minutes. Proteins were 
separated on a SDS-PAGE and analysed by Western blotting. 
2.2.9.2 FLAG-sepharose 
Immunoprecipitations were performed as described in section 2.2.9.1 with the 
following alterations: HCT116 cells were plated onto 15 cm plates 48 hours 
before transfection. Cells were transfected with 8 µg DNA (FLAG-tagged PHD 
plasmids) using Lipofectamine 2000 transfection reagent. After transfection cells 
were incubated under normoxia or hypoxia for 24 hours before they were lysed 
in 1.5 ml TNN lysis buffer as described above. 100 µl of FLAG-agarose slurry 
(Sigma) were washed three times with TNN lysis buffer, added to 25 mg of total 
protein and incubated for 2 hours at 4°C. The samples were centrifuged at 1000 
x g for 5 minutes at 4°C and transferred into a spin column (Biorad, Catalogue 
number 732-6204). Samples were washed three times in washing buffer by 
sequential mixing of the beads with the buffer and removing the buffer by 
centrifuging the buffer into a microfuge tube. After the last wash the dry beads 
were incubated with 2-bed volumes of FLAG peptide (100 µg/ ml, Sigma) in TBS 
for 5 minutes on ice with occasional vortexing. The eluate was removed by 
centrifuging it into a fresh microfuge tube. The elution step was repeated once 
more. Eluates that were previously labelled in heavy and light medium (SILAC) 
were mixed on a 1:1 ratio (volume to volume). The mixed samples were then 
concentrated by centrifugal filtration using a 3 kDa cut-off membrane (Microcon 
Ultracell YM-3, Millipore) at 14,000 x g, 15°C for 120 minutes. Concentrated 
samples were removed from the reservoir by placing the sample reservoir upside 
down in a clean tube and centrifuging it for 1 min at 1000xg. After determining 
the sample volume one quarter volume per volume of 4x NuPage sample buffer 
was added and the sample was denaturated at 57°C for 15 minutes. Samples 
were run on a 10% NuPage gel and further analysed by mass spectrometry 
(section 2.2.10). 
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2.2.9.3 GFP-agarose 
Immunoprecipitations were performed as described in section 2.2.9.1 with a few 
alterations. HEK293 cells were plated onto 15 cm plates 24 hours before 
transfection. Cells were transfected with 4 µg DNA (GFP-actin) using 
Lipofectamine 2000 transfection reagent. The medium was changed to fresh 
medium 5 hours after transfection. Cells were lysed in 1.5 ml ice cold RIPA 
buffer as described above. Samples were immunoprecipitated using 40 µl of GFP-
agarose slurry which was added to 30 mg total protein for 3 hours at 4°C.  The 
beads were washed three times with RIPA buffer. The dry beads were 
resuspended in 40 µl 1x NuPage buffer and boiled for 10 minutes. One tenth of 
the sample was resolved on a 10% NuPage gel next to known amounts of BSA to 
estimate the amount of immunoprecipitated GFP-actin after staining with 
colloidal Coomassie. The rest of the sample was analysed by mass spectrometry 
which was performed by Richard Unwin at the University of Manchester (see 
section 2.2.11). 
2.2.10 SILAC 
Protein samples were separated on 10% Novex gel then stained with coomassie 
(SimplyBlue, Invitrogen). The gel lane was fractionated into 8–12 slices, which 
were each further reduced into 1x1 mm2 fragments then, dehydrated with 
acetonitrile (MeCN). Proteins in each slice were reduced with 10 mM 
dithiothreitol in 50 mM ammonium bicarbonate (AmBic) for 20 min at 56°C then, 
alkylated with 55 mM iodacetamide in 50 mM AmBic for 1 hr at room 
temperature. After this treatment, gel pieces were washed by sequential 
dehydration/hydration steps alternating between MeCN and 50 mM AmBic. 
Polypeptide material was subjected to endoproteolytic digestion with trypsin 
(modified porcine trypsin from Promega) for 90 minutes at 37°C. Digested 
material was extracted from gel pieces with 0.1% trifluoroacetic acid, 5% MeCN, 
and concentrated down to 20 l volume. The digest was separated on an 
Ultimate 3000 nanoLC (Dionex, Sunnyvale, CA). Five l of the sample were pre-
concentrated using a PepMap100 trap column loaded at 20l/min of A solvent 
(5% MeCN, 0.1% formic acid) and separated using a PepMap C18 75-μm i.d. x 15cm 
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analytical column over a 40 min gradient (8-25% B in 30 min then 25-50% B in 10 
min) at a flow rate of 300nl/min (B: 80% MeCN, 0.1% formic acid).  
The nano-LC was coupled to a Q-Star XL (Applied Biosystems, Concorde, ON) and 
Analyst software was used for data dependant acquisition. Basic survey scan (1.5 
s) from 400-1200 Da, was followed by data-dependent MS/MS, of the three most 
intense ions with charge state +2 to +4 for 1.5-2 s. These ions were then 
excluded from acquisition for 30 s. To improve the characterisation of low 
abundant peptide/protein, a gas phase fractionation strategy was applied 
sometimes in combination with an exclusion list generated from the previously 
acquired data. The acquisition was performed over 2 ranges: 400-680 (survey 
scan 2s and 3 EPI scan 4/5/5s) and 660-1500 Da (survey scan 4s and 3 EPI scan 
4/7/10s).  
Acquired tandem mass spectra were exported from Analyst using the script 
Mascot.dll 1.6b23 (matrix Science, London, UK). Mass spectra were recalibrated 
using an in-house script then, searched against UniprotKB-SwissProt database 
(UniProtKB Ver. 9.0-14; databases updated automatically every week) using 
Mascot 2.0 software (Matrix Science) for protein identification with a mass 
tolerance of 30 ppm for the parent and 0.12 Da for the fragments ions. The 
protein identification list was filtered using the non-MUDPit scoring with a 
threshold of 25 (this value was determined by searching the same dataset 
against a randomized database). 
Peptides were quantified with MSQuant (http://msquant.sourceforge.net/) and 
subsequently normalized. Spectra were validated by visual inspection. Identified 
protein could be distributed in three subsets: A) non specific adsorption 
identified in the un-transfected control sample related to the interaction 
between beads and antibodies; B) Un-specific partners equally quantified in the 
un-transfected and EglnX (with X = 1, 2, 3) immunoprecipitation; C) specific 
protein interactions with the EglnX proteins. Protein subsets A and B were used 
to determine the threshold to consider a protein as specifically interacting with 
EglnX. This value was defined as 1.3.  
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2.2.11 Hydroxylation of actin 
Sites of proline hydroxylation were determined by mass spectrometry using the 
MIDAS (MRM-Initiated Detection and Sequencing) methodology on a 4000 Q-Trap 
hybrid triple quadrupole/ion trap mass spectrometer, as described by [122] with 
the following modifications. Gel bands were excised and destained using 100mM 
triethylammonium bicarbonate (TEAB; Sigma)/40% (v/v) acetonitrile. Gel pieces 
were then dehydrated in acetonitrile, and rehydrated in 20µL 50ng/mL modified 
trypsin (Promega) in 100mM TEAB, 5% (v/v) acetonitrile prior to overnight 
incubation at 37°C. Supernatant was removed, remaining peptides extracted 
with 50% (v/v) acetonitrile/0.1% formic acid (Sigma), pooled with the initial 
supernatant and dried in a speedvac. Samples were resuspended in 30µL 2% 
acetonitrile/0.1% formic acid and 2µL used to confirm protein identity by liquid 
chromatography-mass spectrometry [122]. For MIDAS analysis, a list of MRM 
transitions was generated which incorporated proline hydroxylation on all 
potential sites, with one modification and one missed tryptic cleavage allowed 
per peptide. Methionine oxidation was included for target peptide EITALAPSTMK, 
selected due to a potential hydroxylation consensus. Transitions with Q1 >390 
were selected. Q3 mass was set at the predicted mass of a product ion, where 
possible generated by fragmentation at a proline. Collision energy was set at 
(m/z*0.044)+3 for 2+ precursors and (m/z*0.04)+2 for 3+ precursors, and dwell 
time was fixed at 60ms. Samples were analysed using this list if MRM transitions 
to trigger MS/MS fragmentation as previously described by Unwin [122]. Data was 
processed using MASCOT with proline hydroxylation as a variable modification, 
1x missed cleavage. Putative sites of proline hydroxylation were confirmed by 
manual inspection. 
2.2.12 Immunostaining 
Cells were seeded on sterile cover slips in 6 well plates and transfected with 
GFP-actin as described in section 2.2.4 or treated as described in section2.2.5. 
Cells were washed twice with PBS before they were fixed in 4% formalin for 10 
minutes at room temperature. Cells were washed three times with PBS and then 
permeabilised in 1% triton X-100 for 10 minutes at 4°C. After another two 
washes with PBS unspecific binding was blocked with 10% BSA for 30 minutes at 
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room temperature. Samples were stained using Cy3- or FITC- linked anti FLAG 
antibody (Sigma), Phalloidin-TRITC (Sigma) or DNAseI-Alexa488 (Invitrogen) for 2 
hours or overnight at room temperature in a humid environment. Phalloidin is a 
fungal toxin isolated from Amanita phalloides. Phalloidin binds to and stabilises 
actin filaments. It only binds actin oligomers and polymers but not actin 
monomers [123]. DNAseI however is used to visualise actin monomers. DNAseI 
binds actin monomers with high affinity and actin polymers with low affinity 
[124]. After staining samples were washed three times with PBS. Any excess 
liquid was drained from the cover slips before they were mounted onto 
microscopy slides using vectrashield mounting medium (Vector laboratories Inc.) 
and sealed with nail varnish. Samples were analysed using a Leica SP2 Confocal 
microscope with LCS software. 
2.2.13 Quantification of filamentous actin 
This assay was performed as described previously by Machesky and Hall [125]. 
Briefly, cells were seeded onto 6cm dishes, transfected as described in section 
2.2.4 or treated as described in section 2.2.5 and then grown to confluency.  
Cells were washed twice in PBS, then lysed and fixed in 250 µl lysis buffer 
containing a saturating amounts of Phalloidin (20 mM KPO4 pH 8, 10 mM Pipes pH 
8, 5 mM EGTA pH 8, 2 mM MgCl2, 0.1% TritonX-100, 3.7% formalin, 2 M 
Phalloidin-TRITC) and incubated for 1 hour at room temperature whilst slowly 
rotating. Protein concentration was measured as described in section 2.2.6. The 
sample was centrifuged at 12,000 x g for 2 minutes in a table top centrifuge. 
The pellet was washed with washing buffer (0.1% Saponin, 20 mM KPO4 pH 8, 10 
mM Pipes pH 8, 5 mM EGTA pH 8, 2 mM MgCl2) and centrifuged again at 12,000 x 
g for 2 minutes. The Phalloidin bound to the actin filaments was extracted with 
methanol. 200 µl methanol were added to the pellet and incubated for 1 hour at 
room temperature whilst slowly rotating. Samples were centrifuged at 12,000 x 
g for 2 minutes in a table top centrifuge. The fluorescence emission of the 
supernatants was measured in a 96well plate at 570 nm and an excitation at 540 
nm. 
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2.2.14 Wound healing scratch assay 
Transfected or untransfected cells were grown to confluency and treated 
accordingly (as described in section 2.2.5). A p200 pipette tip was used to 
scratch a wound into the cell monolayer. Cells were washed once with sterile 
PBS to remove any debris before they were placed into a low serum medium 
(DMEM supplemented with 1% FBS and 2 mM L-glutamine). The closure of the 
wound was tracked using the Nikon TE 2000 timelapse microscope. Images were 
taken for three different fields of each condition every ten minutes for 290 
minutes (U2OS cells) or 590 minutes (A375 cells). Analysis of wound closure was 
carried out using the single cell tracking device of ImageJ. This was done to 
account for differences in wound width and resulted in calculation of distances 
and cellular velocity. 
2.2.15 Inverse invasion assay 
This method is a modified version of the method described by Hennigan [126]. 
An aliquot of matrigel was thawed slowly on ice and then diluted 1:1 with ice 
cold PBS. 100 µl of the matrigel/PBS solution was pipetted in each transwell 
chamber which was inserted into a well of a 24well plate (Fisher, catalogue 
number TKT-525-110X). The matrigel was left to settle for 1 hour at 37°C in a 
humidified incubator. In the meantime a cell suspension of 4 x 105 cells per ml 
was prepared in complete medium (DMEM containing 10% FBS). The transwells 
were inverted onto the lid of the 24well plate and 100 µl of the cell suspension 
was pipetted onto the underside of each transwell filter (4 x 104 cells plated). 
The transwells were carefully covered with the base of the 24well plate so that 
the plate contacts the droplet of the cell suspension. The inverted plate was 
incubated at 37°C in a humidified incubator for 4 hours to allow the cells to 
attach. Each transwell was removed and sequentially dipped into 2x 1 ml of 
serum free medium to wash off the serum and then in placed the right way up in 
1 ml of serum free medium in a fresh 24well plate. 100 µl of complete medium 
(DMEM containing 10% FBS) were pipetted on top of the matrigel plug. The plate 
was incubated at 37°C for 3 days. 
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After that the transwells were transferred to a fresh 24well plate and overlaid 
with 1 ml of a 1 µM Calcein-AM solution diluted in serum free medium 
(acetoxymethylester of calcein, Molecular Probes).  Calcein stains the whole cell 
fluorescent green. After 1 hour incubation at 37°C the assay was analysed by 
confocal microscopy using a Leica SP2 microscope. Transwells were placed onto 
large coverslips on a 20x objective and analysed by optical sectioning (Z-
sections). Optical sections were taken every 15 µm starting from the bottom of 
the matrigel plug producing a series of images. Individual optical sections are 
placed alongside one another with increasing depth as indicated. Invasion assays 
were quantified by measuring the fluorescence intensity of cells penetrating the 
matrigel to a depth of 45 µm and greater. This intensity was expressed as a 
percentage of the total fluorescence intensity of all cells within the plug. Data 
were normalized for each experiment such that invasion of cells transfected 
with scrambled control shRNA under normoxia =1. The fluorescence intensity of 
each image was quantified using ImageJ. Overall results were determined from 
at least three different experiments with duplicate samples.  
2.2.16 Statistical analysis 
Experiments were repeated at least three times, images shown are 
representative results from one experiments. In graphs results are presented as 
mean ± S.E.M. Statistical significance of differences between the means was 
determined by Mann-Whitney test analysis using GraphPad Prism 5. Values of p < 
0.05 were selected to be statistically significant. 
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3 Quantitative proteomic screen to identity new 
targets of PHDs 
3.1 Introduction 
HIF prolyl hydroxylases (PHDs) have been implicated to function in different 
pathways, however their substrates are mostly unknown. In order to identify 
new potential substrates of PHDs, a quantitative proteomic approach (SILAC) was 
used. Co-immunoprecipitations using FLAG-tagged PHDs were performed under 
normoxia and hypoxia and binding of proteins was compared to each other or to 
a mock transfected sample. Cells were grown in two cultures, one in normal 
medium, the second one in medium containing 13C-labelled arginine and lysine. 
Labelling of arginine and lysine leads to labelling of all peptides after tryptic 
digest but the carboxyterminal peptide of the protein due to the specificity of 
trypsin to cleave at these amino acids. Furthermore, cells are grown in dialysed 
serum so there are no other means of incorporating amino acids. Potential 
binding partners are identified by mass spectrometry after co-
immunoprecipitations. Peptide pairs are separated by a distinct mass difference. 
Quantification of peptides is achieved by comparing peak ratios to each other 
whereby quantification is only limited by peptide signal and signal-to-noise 
ratio. 
3.2 Results 
3.2.1 PHD substrates can be trapped on the enzyme under 
hypoxia 
Before identifying new potential substrates of prolyl hydroxlases in a 
quantitative proteomic approach, the best binding conditions between the 
enzyme and its substrate had to be identified.-ketoglutarate-dependent 
oxygenases are thought to function by a common mechanism as was shown for 
the asparaginyl hydroxylase Factor Inhibiting HIF (FIH), which is involved in the 
regulation of HIF activity. First the enzyme binds the prime protein substrate 
and -ketoglutarate before it binds molecular oxygen [30]. Under conditions 
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with sufficient concentrations of all co-substrates, the complex dissociates after 
hydroxylation of a specific prolyl residue. In order to identify new substrates of 
PHDs the enzyme-substrate complex had to be stabilised. According to the above 
model oxygen deprivation or blocking enzyme activity with -ketoglutarate like 
inhibitors may prolong the interaction. Co-immunoprecipitations using FLAG-
tagged PHD2 were performed under normoxic and hypoxic conditions as well as 
in the presence of hypoxia mimetic agents like DMOG, a non-cleavable -
ketoglutarate derivative that blocks PHD enzyme activity [18]. The enzyme-
substrate interaction between PHD2 and HIF1 was investigated under different 
conditions using a renal clear cell carcinoma cell line (RCC4), which lacks the 
von Hippel-Lindau protein (pVHL). As pVHL is the recognition component of the 
E3 ubiquitin ligase complex that targets the HIF subunit for proteasomal 
degradation, HIFcannot be degraded in these cells and is stable even under 
normoxia (Figure 3.1a, lane 1). 
As shown in Figure 3.1a (lane 4) the enzyme and its substrate only showed a 
weak interaction under normoxic conditions even in the absence of pVHL. The 
PHD inhibitor DMOG (lane 5) had little effect on the binding. However, under 
hypoxic conditions the PHD-HIF interaction increased (lane 6). This indicates 
that the PHD2-HIF1 complex is not a stable entity under normoxia, and is only 
slightly stabilised by DMOG. However, 1% oxygen significantly stabilises the 
enzyme-substrate complex. The -ketoglutarate derivative DMOG might 
sterically hinder the binding of the substrate to the enzyme, which could 
account for the difference between hypoxia and pharmacological inhibition of 
the enzyme. 
Similar results were obtained for the interaction of PHD3 and HIF1 (Figure 
3.1b). Although PHD3 is not thought to be the major hydroxylase of HIF1, it has 
been shown to be able to hydroxylate, and therefore must bind, HIF1in vitro 
[32]. In addition to the conditions described above, we also used a cell-
permeable -ketoglutarate derivative (TKG) that increases intracellular -
ketoglutarate levels and reactivates PHDs under hypoxia [36]. It would not be 
expected to stabilise the enzyme-substrate complex. This is indeed the case in 
Figure 3.1b, lane 3.  
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Figure 3.1: Binding conditions that stabilise the enzyme-substrate (PHD-HIF1) complex 
Binding conditions that stabilise the enzyme-substrate complex were tested in RCC4 cells. 
Co-immunoprecipitations of FLAG-tagged PHD2 (a) or PHD3 (b) with HIF1a were performed 
under normoxia or hypoxia. Where indicated, cells were also treated with either a PHD 
inhibitor or an activator – DMOG or a cell-permeable -ketoglutarate derivative (TKG), 
respectively. 
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These results indicate that under normoxic conditions the enzyme and its 
substrates are only briefly in a complex. Under conditions where oxygen is 
limiting the prime protein substrate is trapped on the enzyme as oxygen is the 
last co-substrate to bind the enzyme. These results allowed us to define the 
optimal conditions under which to isolate PHD-binding proteins. 
 
3.2.2 Incorporation of heavy amino acids in HCT116 cells 
HCT116 cells were grown in heavy or light medium for two weeks, before 
incorporation of heavy amino acids was tested. HCT116 cells were used as they 
are routinely used in the lab and are well characterised regarding their hypoxic 
response. Total cell lysates were separated on a SDS-PAGE, bands were cut out 
as shown in Figure 3.2 and analysed by mass spectrometry. 
 
 
Figure 3.2: Check incorporation of amino acids 
Total cell lysates of cells grown in heavy or light cultures were separated on SDS-PAGE, 
bands as indicated were cut out and analysed by mass spectrometry. 
 
Incorporation time was tested previously in a time course experiments in which 
cells were lysed every day until incorporation reached 100%. For HCT116 cell 
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complete incorporation of labelled amino acids takes about two weeks. 
Complete incorporation was checked before each SILAC experiment. 
 
3.2.3 SILAC screen 
To be able to directly compare samples to each other, a quantitative proteomic 
approach was used [115]. FLAG-tagged PHDs were overexpressed in the human 
colon carcinoma cell line HCT116. Co-immunoprecipitations using anti-FLAG 
antibody were performed under normoxia and/or hypoxia. After eluting proteins 
from the column, equal amounts of eluates of labelled and unlabelled sample 
were mixed and concentrated using centricon tubes. These samples were 
resolved on SDS PAGE and after tryptic in-gel digest, peptides were identified by 
mass spectrometry. The tryptic peptides of each sample showed a specific mass 
difference, allowing samples to be directly compared to each other. The 
workflow is depicted in Figure 3.3. The mass spectrometric analyses of this 
quantitative screen were performed by Willy Bienvenut (Beatson Institute for 
Cancer Research). 
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Figure 3.3: Scheme of the quantitative proteomic screen (SILAC).  
HCT116 cells were grown in two different cultures (heavy and light amino acids containing 
medium). FLAG-tagged PHDs were overexpressed and co-immunoprecipitations using anti-
FLAG antibody were performed under normoxia (heavy) or hypoxia (light) before samples 
were mixed in a 1:1 ratio and resolved on SDS PAGE. After tryptic in-gel digest, peptides 
were identified by mass spectrometry and quantified (the ratio between light and heavy of 
each identified peptide). 
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3.2.4 Assessment of the hypoxic response in HCT116 cells 
HCT116 cells were incubated under normoxic or hypoxic conditions for either 6 
or 18 hours. Hypoxic cells were either lysed under hypoxia or re-oxygenated for 
10 minutes before lysis. The expression of each of the PHD isoforms as well as 
HIF1 was analysed by immunoblot analysis (Figure 3.4). 
 
 
Figure 3.4: Assessment of the hypoxic response in HCT116 cells 
Immunoblot analysis showing the expression of each of PHD isoforms and HIF1 under 
normoxia, hypoxia and after 10 minutes of re-oxygenation at two different time points (6 
hours or 18 hours). 
 
As shown in Figure 3.4 expression of endogenous PHD1 was independent of 
ambient oxygen conditions whereas levels of endogenous PHD2 and PHD3 were 
upregulated under hypoxia. However, expression of PHD3 was upregulated at an 
earlier timepoint than expression of PHD2. HIF1 was stabilised under hypoxia 
but degraded within 10 minutes of re-oxygenation.  
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3.2.4.1 Results for PHD3 
Firstly, the conditions for the larger scale co-immunoprecipitation used for the 
SILAC screen were optimised. Co-immunoprecipitations were performed with 
overexpressed FLAG-tagged PHD3 using anti FLAG antibodies. Cultures 
overexpressing FLAG-tagged PHD3 were grown under normoxia or hypoxia. 
Experiments were controlled for by adding fresh media after transfection and 
using a constant protein amount for the immunoprecipitation. 
 
 
Figure 3.5: Testing the conditions for the large-scale co-immunoprecipitation using FLAG-
tagged PHD3 
FLAG-tagged PHD3 was overexpressecd in HCT116 cells in normoxic or hypoxic conditions 
and immunoprecipitated using anti FLAG antibodies covalently linked to sepharose beads. 
 
FLAG-tagged PHD3 was immunoprecipitated efficiently using the conditions 
described in section 2.2.9.2 (Figure 3.5). However, it has to be kept in mind that 
overexpresssion of FLAG-tagged PHD3 was able to induce cell death as reported 
previously [71]. 
Next, cultures overexpressing FLAG-tagged PHD3 grown in normoxia as well as 
samples overexpressing an empty vector control grown in hypoxia were grown in 
heavy medium whereas samples overexpressing FLAG-tagged PHD3 grown in 
hypoxia and samples overexpressing an empty vector control grown in normoxia 
were grown in light (normal) medium. Different samples could then be compared 
to each other. The most important samples are the ones comparing PHD3-
transfected samples under hypoxia and normoxia to each other using the 
substrate trap. 
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Figure 3.6: SILAC analysis of immunoprecipitations of PHD3-FLAG 
(a) PHD3-FLAG or empty vector control (pFLAG) were overexpressed in HCT116 cells grown 
in heavy or light medium and immunoprecipitated using anti FLAG antibodies. Eluates after 
immunoprecipitation were mixed in a 1:1 ratio as indicated. Concentrated samples were 
resolved on SDS-PAGE, stained with coomassie, lanes were cut into strips as indicated and 
analysed by mass spectrometry. (b) Immunoblot analysis to confirm expression of PHD3-
FLAG (c-e) ratios of mass spectrometric analysis of samples indicated. Ratios >1.5 were 
considered significant changes. 
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Table 3.1: SILAC analysis of samples overexpressing PHD3-FLAG 
  Description 
Accession 
number 
number 
of 
peptides 
ratio PHD3 
hypoxia/ 
PHD3 
normoxia >1.5
1 Methylosome subunit pICln P54105 24 1.72
2 Actin, cytoplasmic 2 P63261 27 1.78
3 Creatine kinase B-type P12277 3 2.14
     
  
 
  
  Description 
Accession 
number 
number 
of 
peptides 
ratio PHD3 
normoxia/ 
untransfected 
normoxia >1.5
1 Profilin-1 P07737 1 2.03
2 Actin, cytoplasmic 2 P63261 7 1.52
3 Mps one binder kinase activator-like 2 Q70IA6 1 1.54
  
 
  
  
 
  
  Description 
Accession 
number 
number 
of 
peptides 
ratio PHD3 
hypoxia/ 
untransfected 
hypoxia >1.5 
1 Junction plakoglobin P14923 7 2.14
2 Peroxiredoxin-1 Q06830 2 2.09
3 Filaggrin-2 Q5D862 2 1.68
 
 
While binding of most of the identified proteins did not change between 
normoxia and hypoxia, there were a few that showed a difference with 
increased binding under hypoxia (Figure 3.6b). The protein creatine kinase 
showed one of the highest ratios, but was only identified with 3 peptides in this 
screen. The second highest ratio was a 2-fold increase in binding under hypoxia 
for actin (identified with 27 peptides).  
Furthermore samples transfected with PHD3-FLAG were compared to samples 
transfected with an empty vector control either under normoxia or under 
hypoxia. The proteins shown in Table 3.1 were identified to bind to PHD3 under 
these conditions, however these proteins were only identified with low peptide 
counts in one run of the experiment. 
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3.2.4.2 Results for PHD1 
Subsequently, co-immunoprecipitations were performed overexpressing FLAG-
tagged PHD1. Cultures were set up as described in section 3.2.4.1. 
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Figure 3.7: SILAC analysis of immunoprecipitations of PHD1-FLAG 
(a) PHD1-FLAG or empty vector control (pFLAG) were overexpressed in HCT116 cells grown 
in heavy or light medium and immunoprecipitated using anti FLAG antibodies. Eluates after 
immunoprecipitation were mixed in a 1:1 ratio as indicated. Concentrated samples were 
resolved on SDS-PAGE, stained with coomassie, lanes were cut into strips as indicated and 
analysed by mass spectrometry. (b) Immunoblot analysis to confirm expression of PHD1-
FLAG (c-e) ratios of mass spectrometric analysis of samples indicated. Ratios >1.5 were 
considered significant changes.. 
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Table 3.2: SILAC analysis of samples overexpressing PHD1-FLAG 
  Description 
Accession 
number 
number 
of  
peptides 
ratio PHD1 
hypoxia/ 
PHD1 
normoxia >1.5
1 Actin, cytoplasmic 1  P60709 25 1.93
2 Glyceraldehyde-3-phosphate dehydrogenase  P04406 2 2.41
3 Heat shock protein HSP 90-alpha  P07900 19 1.78
4 Heat shock protein HSP 90-beta  P08238 23 1.68
     
     
  Description 
Accession 
number 
number 
of  
peptides 
ratio PHD1 
normoxia/ 
untransfected 
normoxia >1.5
1 Egl nine homolog 2  Q96KS0 14 33.83
2 LIM and SH3 domain protein 1  Q14847 1 2.56
3 Small nuclear ribonucleoprotein Sm D2  P62316 4 1.55
4 Methylosome protein 50  Q9BQA1 20 1.81
5 Methionine adenosyltransferase 2 subunit beta  Q9NZL9 2 2.50
6 60S ribosomal protein L7a  P62424 4 1.90
7 Mps one binder kinase activator-like 2  Q70IA6 1 2.26
8 
Heterogeneous nuclear ribonucleoproteins 
A2/B1  P22626 4 1.50
9 Protein phosphatase 1A  P35813 24 1.85
10 
Dolichyl-diphosphooligosaccharide--protein       
glycosyltransferase 48 kDa subunit  P39656 2 2.15
11 Serine/threonine-protein kinase 38  Q15208 9 1.96
12 Talin-1  Q9Y490 3 2.75
13 Protein arginine N-methyltransferase 5  O14744 55 1.84
14 Small nuclear ribonucleoprotein Sm D1  P62314 3 1.67
15 Spectrin beta chain, brain 1  Q01082 3 1.87
16 Protein phosphatase 1B  O75688 69 1.71
17 Eukaryotic translation initiation factor 3 subunit C  Q99613 4 2.11
18 Ubiquitin carboxyl-terminal hydrolase 15  Q9Y4E8 4 1.68
19 DNA replication licensing factor MCM2  P49736 1 2.09
20 Hypoxia up-regulated protein 1  Q9Y4L1 3 1.92
21 Serine hydroxymethyltransferase, mitochondrial P34897 2 2.72
22 
26S proteasome non-ATPase regulatory subunit 
2 Q13200 4 1.55
23 Ras GTPase-activating-like protein IQGAP1  P46940 4 2.29
24 T-complex protein 1 subunit epsilon  P48643 7 1.63
25 T-complex protein 1 subunit alpha  P17987 7 2.12
26 C-1-tetrahydrofolate synthase, cytoplasmic  P11586 3 1.83
27 DNA replication licensing factor MCM3  P25205 3 1.89
28 Filamin-B  O75369 3 1.51
29 T-complex protein 1 subunit eta  Q99832 6 1.63
30 Importin subunit beta-1  Q14974 4 2.71
31 Heat shock protein 105 kDa  Q92598 4 2.19
32 Neutral alpha-glucosidase AB  Q14697 7 2.17
33 
6-phosphogluconate dehydrogenase, 
decarboxylating  P52209 2 1.50
34 T-complex protein 1 subunit zeta  P40227 6 2.15
35 Vinculin  P18206 8 1.87
36 Glutathione reductase, mitochondrial  P00390 4 1.70
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37 
Ankyrin repeat and FYVE domain-containing 
protein 1 Q9P2R3 3 2.14
38 Lamin-A/C P02545 3 1.50
39 Polypyrimidine tract-binding protein 1 P26599 3 1.91
40 60S ribosomal protein L22 P35268 2 2.77
41 
Isocitrate dehydrogenase (NAD) subunit alpha, 
mitochondrial       P50213 1 1.70
42 Adenylate kinase isoenzyme 2, mitochondrial P54819 2 3.71
43 DNA replication licensing factor MCM6 Q14566 1 1.92
44 Uncharacterized protein C11orf84 Q9BUA3 2 1.98
45 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3       Q16875 4 1.87
46 Far upstream element-binding protein 2 Q92945 2 2.80
47 Serine/threonine-protein kinase RIO1 Q9BRS2 2 3.08
48 Poly (ADP-ribose) polymerase 1 P09874 4 1.92
49 Peroxiredoxin-5, mitochondrial P30044 3 2.62
50 40S ribosomal protein S16 P62249 7 1.69
51 Nuclease-sensitive element-binding protein 1 P67809 2 1.73
52 Splicing factor, proline- and glutamine-rich P23246 3 2.09
53 Polyadenylate-binding protein 1 P11940 8 1.67
54 Phosphatidylethanolamine-binding protein 1 P30086 1 1.76
55 BTB/POZ domain-containing protein KCTD5 Q9NXV2 4 2.10
56 Prohibitin P35232 2 1.69
57 OTU domain-containing protein 4 Q01804 4 1.73
58 Splicing factor 3B subunit 1 O75533 1 1.86
59 ATP-dependent DNA helicase 2 subunit 1 P12956 2 1.75
60 
Staphylococcal nuclease domain-containing 
protein 1 Q7KZF4 3 1.54
61 FACT complex subunit SPT16 Q9Y5B9 10 1.66
62 40S ribosomal protein S19 P39019 3 2.37
63 Spectrin alpha chain, brain Q13813 2 3.21
64 
Mitogen-activated protein kinase kinase kinase      
7-interacting protein 1 Q15750 2 2.30
65 40S ribosomal protein S12 P25398 5 2.04
66 Heterogeneous nuclear ribonucleoprotein A1 P09651 2 1.65
67 Heterogeneous nuclear ribonucleoprotein A/B Q99729 1 2.59
68 60S ribosomal protein L9 P32969 2 2.89
69 Tyrosine-protein kinase JAK1 P23458 3 2.80
70 40S ribosomal protein S11 P62280 2 1.53
71 Gelsolin P06396 2 1.62
72 26S protease regulatory subunit 7 P35998 3 2.11
73 60S ribosomal protein L3 P39023 1 1.97
74 40S ribosomal protein S23 P62266 1 3.99
75 40S ribosomal protein S24 P62847 1 3.68
76 60S ribosomal protein L30 P62888 3 1.78
77 FACT complex subunit SSRP1 Q08945 2 1.71
78 Interleukin enhancer-binding factor 2 Q12905 2 2.27
79 Reticulocalbin-1 Q15293 2 1.98
80 Keratin, type II cytoskeletal 71 Q3SY84 2 1.65
81 
Putative small nuclear ribonucleoprotein 
polypeptide E-like       protein 1 Q5VYJ4 2 3.06
82 AN1-type zinc finger protein 1 Q8TCF1 2 2.97
83 U4/U6 small nuclear ribonucleoprotein Prp31 Q8WWY3 1 3.69
84 
Synaptic vesicle membrane protein VAT-1 
homolog Q99536 1 2.58
85 UPF0160 protein MYG1 Q9HB07 1 2.29
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86 RuvB-like 2 Q9Y230 2 1.75
     
     
  Description 
Accession 
number 
number 
of  
peptides 
ratio PHD1 
hypoxia/ 
untransfected 
hypoxia >1.5 
1 Egl nine homolog 2  Q96KS0 31 9.69
2 Histone H1.4  P10412 4 4.04
3 40S ribosomal protein S2  P15880 2 3.20
4 Tropomyosin alpha-4 chain  P67936 7 3.13
5 Phosphate carrier protein, mitochondrial  Q00325 1 2.84
6 Small nuclear ribonucleoprotein Sm D3  P62318 2 2.76
7 GTP-binding nuclear protein Ran  P62826 7 2.73
8 
Nascent polypeptide-associated complex subunit 
alpha        Q13765 3 2.68
9 60S ribosomal protein L8  P62917 1 2.60
10 Rho GDP-dissociation inhibitor 1  P52565 2 2.54
11 40S ribosomal protein S3  P23396 11 2.49
12 Spindlin-1  Q9Y657 3 2.45
13 Glutathione transferase omega-1  P78417 2 2.36
14 40S ribosomal protein S4, X isoform  P62701 4 2.35
15 Chloride intracellular channel protein 1  O00299 6 2.32
16 
Guanine nucleotide-binding protein subunit beta-
2-like 1        P63244 3 2.31
17 Methylosome subunit pICln  P54105 21 2.30
18 Triosephosphate isomerase  P60174 12 2.30
19 Malate dehydrogenase, mitochondrial  P40926 11 2.25
20 Glutathione S-transferase P  P09211 4 2.17
21 Annexin A5  P08758 8 2.12
22 L-lactate dehydrogenase B chain  P07195 17 2.11
23 Elongation factor 1-delta  P29692 9 2.10
24 60S ribosomal protein L7  P18124 4 2.07
25 14-3-3 protein zeta/delta  P63104 19 2.06
26 14-3-3 protein theta  P27348 3 2.03
27 LIM and SH3 domain protein 1  Q14847 3 2.01
28 60S ribosomal protein L23a  P62750 1 1.99
29 40S ribosomal protein S18  P62269 7 1.97
30 Malate dehydrogenase, cytoplasmic  P40925 2 1.92
31 40S ribosomal protein S25  P62851 5 1.88
32 NAD(P)H dehydrogenase (quinone) 1  P15559 4 1.86
33 Heterogeneous nuclear ribonucleoprotein D0  Q14103 2 1.86
34 14-3-3 protein epsilon  P62258 13 1.85
35 60S ribosomal protein L27a  P46776 3 1.83
36 60S ribosomal protein L27  P61353 4 1.78
37 60S ribosomal protein L11  P62913 2 1.77
38 60S ribosomal protein L31  P62899 1 1.76
39 S-adenosylmethionine synthetase isoform type-2 P31153 1 1.75
40 Small nuclear ribonucleoprotein Sm D2  P62316 5 1.74
41 Methylosome protein 50  Q9BQA1 25 1.68
42 Methionine adenosyltransferase 2 subunit beta  Q9NZL9 1 1.62
43 60S ribosomal protein L7a  P62424 3 1.60
44 L-lactate dehydrogenase A chain  P00338 12 1.60
45 Mps one binder kinase activator-like 2  Q70IA6 5 1.57
46 Coproporphyrinogen III oxidase, mitochondrial  P36551 3 1.57
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47 Peroxiredoxin-6  P30041 18 1.56
48 Heat shock protein beta-1  P04792 2 1.56
49 Annexin A3  P12429 7 1.56
50 
Heterogeneous nuclear ribonucleoproteins 
A2/B1  P22626 4 1.54
51 60S acidic ribosomal protein P0  P05388 3 1.54
52 Nucleoside diphosphate kinase A  P15531 11 1.54
53 Creatine kinase B-type  P12277 3 1.51
54 Protein phosphatase 1A  P35813 29 1.51
 
 
In Figure 3.7 the results obtained for cells overexpressing PHD1-FLAG are shown. 
Only a few proteins were identified to show increased binding under hypoxia 
compared to normoxia (Table 3.2). Glyceraldehyde-3-phosphate dehydrogenase 
showed the highest ratio, but was only identified with two peptides in this 
screen. The second highest ratio was a 2-fold increase in binding under hypoxia 
for actin (identified with 25 peptides). Another protein identified to bind 
stronger under hypoxia was heat shock protein HSP-90. 
Apart from this samples transfected with PHD1-FLAG were compared to samples 
transfected with an empty vector control either under normoxia or under 
hypoxia. Identified proteins are shown in Table 3.2. Most of these proteins were 
only identified with low peptide counts. Only a few proteins were identified with 
higher peptide counts and therefore higher confidence of a real interaction. 
Proteins binding stronger under normoxia compared to the control were protein 
phosphatase 1A/1B and protein arginine N-methyltransferase. The most 
prominent proteins binding stronger under hypoxia compared to the control were 
a few metabolic enzymes such as triosephosphate isomerase, malate 
dehydrogenase and lactate dehydrogenase among a other proteins such as 
peroxiredoxin, nucleoside diphosphate kinase and protein phosphatase 1A. 
 
3.2.4.3 Results for PHD2 
Lastly, co-immunoprecipitations were performed overexpressing FLAG-tagged 
PHD2. Cultures were set up as described in section 3.2.4.1. 
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Figure 3.8: SILAC analysis of immunoprecipitations of PHD2-FLAG 
(a) PHD2-FLAG or empty vector control (pFLAG) were overexpressed in HCT116 cells grown 
in heavy or light medium and immunoprecipitated using anti FLAG antibodies. Eluates after 
immunoprecipitation were mixed in a 1:1 ratio as indicated. Concentrated samples were 
resolved on SDS-PAGE, stained with coomassie, lanes were cut into strips as indicated and 
analysed by mass spectrometry. (b) Immunoblot analysis to confirm expression of PHD2-
FLAG (c-e) ratios of mass spectrometric analysis of samples indicated. Ratios >1.5 were 
considered significant changes. 
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Table 3.3: SILAC analysis of samples overexpressing PHD2-FLAG 
  Description 
Accession 
number 
number 
of 
peptides 
ratio PHD2 
hypoxia/ 
PHD2 
normoxia 
>1.5 
1 Small nuclear ribonucleoprotein Sm D3 P62318 3 1.50
2 Macrophage migration inhibitory factor  P14174 2 1.53
3 Fructose-bisphosphate aldolase A  P04075 4 1.25
4 Actin, cytoplasmic 2  P63261 38 1.70
5 L-lactate dehydrogenase B chain  P07195 6 1.38
6 Actin, cytoplasmic 1  P60709 1 1.62
7 L-lactate dehydrogenase A chain  P00338 6 1.32
8 
Eukaryotic translation initiation factor 3 subunit 
F        O00303 2 1.51
9 Heat shock protein 75 kDa, mitochondrial  Q12931 2 2.02
10 Alpha-2-macroglobulin  P01023 2 2.02
  
 
  
  
 
  
  Description 
Accession 
number 
number 
of 
peptides 
ratio PHD2 
normoxia/ 
untransfected 
normoxia 
>1.5 
1 Egl nine homolog 1 Q9GZT9 34 54.36
2 OTU domain-containing protein 4  Q01804 7 1.64
3 Splicing factor 3B subunit 3  Q15393 6 1.60
4 
Mitogen-activated protein kinase kinase kinase    
7-interacting protein 1  Q15750 4 1.63
5 60S ribosomal protein L24  P83731 5 1.56
6 Protein phosphatase 1A  P35813 4 1.50
7 Protein arginine N-methyltransferase 5  O14744 58 2.01
8 Ubiquitin carboxyl-terminal hydrolase 15  Q9Y4E8 5 1.65
9 
Ankyrin repeat and FYVE domain-containing 
protein 1  Q9P2R3 3 1.68
10 Methylosome protein 50  Q9BQA1 28 2.15
11 Kinesin-like protein KIF11  P52732 2 1.69
12 Filamin-A  P21333 20 1.78
13 Protein phosphatase 1B  O75688 78 1.66
14 T-complex protein 1 subunit eta  Q99832 4 1.69
15 Polyadenylate-binding protein 1  P11940 3 1.70
16 T-complex protein 1 subunit alpha  P17987 8 1.54
17 Vinculin  P18206 7 1.74
18 RNA-binding protein 10  P98175 7 1.87
19 Methylosome subunit pICln  P54105 9 1.67
20 T-complex protein 1 subunit theta  P50990 15 1.51
21 
Leucine-rich PPR motif-containing protein, 
mitochondrial       P42704 8 1.91
22 Stress-70 protein, mitochondrial  P38646 10 1.67
23 
Non-POU domain-containing octamer-binding 
protein  Q15233 2 5.69
24 60S ribosomal protein L22  P35268 2 3.62
25 
26S proteasome non-ATPase regulatory 
subunit 1  Q99460 3 1.69
26 14-3-3 protein zeta/delta  P63104 2 1.53
27 Adenosylhomocysteinase  P23526 9 1.46
28 Keratin, type I cytoskeletal 18  P05783 15 1.54
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29 Tyrosine-protein kinase JAK1  P23458 10 1.90
30 DNA-dependent protein kinase catalytic subunit P78527 5 1.99
31 Exportin-2 P55060 2 2.63
32 Kinesin-1 heavy chain P33176 2 2.35
33 Lamin-A/C P02545 2 2.28
34 Coatomer subunit beta' P35606 2 2.24
35 60S ribosomal protein L18 Q07020 2 2.07
36 Ribose-phosphate pyrophosphokinase 2 P11908 2 2.07
37 Vigilin Q00341 2 2.01
38 Integrin beta-1 P05556 3 1.92
39 3-hydroxyacyl-CoA dehydrogenase type-2 Q99714 2 1.89
40 40S ribosomal protein S3a P61247 3 1.86
41 FACT complex subunit SPT16 Q9Y5B9 4 1.81
42 6-phosphofructokinase type C Q01813 1 1.77
43 Splicing factor 3B subunit 1 O75533 1 1.75
44 ATP-dependent RNA helicase A Q08211 4 1.69
45 
Eukaryotic translation initiation factor 2 subunit 
1       P05198 4 1.63
46 Eukaryotic translation initiation factor 3 subunit I  Q13347 4 1.58
47 Methionine adenosyltransferase 2 subunit beta Q9NZL9 2 1.54
48 Coatomer subunit alpha P53621 5 1.53
  
 
  
  
 
  
  Description 
Accession 
number 
number 
of 
peptides 
ratio PHD2 
hypoxia/ 
untransfected 
hypoxia >1.5 
1 Egl nine homolog 1 Q9GZT9 33 7.42
2 Ig kappa chain V-II region Cum  P01614 1 5.22
3 Keratin, type I cytoskeletal 10  P13645 4 4.42
4 Creatine kinase B-type P12277 3 2.29
5 
S-adenosylmethionine synthetase isoform type-
2  P31153 2 1.95
6 Fascin Q16658 3 1.90
7 OTU domain-containing protein 4  Q01804 2 1.88
8 Splicing factor 3B subunit 3  Q15393 3 1.87
9 
Mitogen-activated protein kinase kinase kinase    
7-interacting protein 1  Q15750 3 1.82
10 Small nuclear ribonucleoprotein Sm D3 P62318 2 1.54
11 Keratin, type I cytoskeletal 9  P35527 3 1.51
 
 
In Figure 3.8 the results obtained for cells overexpressing PHD2-FLAG are shown. 
As seen before some proteins were identified to show increased binding under 
hypoxia compared to normoxia (Table 3.3), however most of them were only 
identified with low peptide counts. Actin was found to have the highest ratio as 
well as the highest peptide count under these conditions. 
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When samples transfected with PHD2-FLAG were compared to samples 
transfected with an empty vector control either under normoxia or under 
hypoxia, most identified proteins were only identified with low peptide counts, 
especially under hypoxic conditions. The most prominent proteins binding 
stronger under normoxia compared to the control were tyrosine-protein kinase 
JAK1, protein phosphatase 1B, filamin-A and protein arginine N-
methyltransferase. 
Overall, using the substrate trap actin appears to be the most promising 
candidate as it was identified to bind stronger under hypoxia than under 
normoxia in two experimental runs for PHD3 as well for PHD1 and PHD2 with 
high ratios and high peptide counts. Therefore, it was validated further as a 
potential substrate. 
 
3.3 Conclusions 
In initial binding experiments, we found that the substrate can be trapped on 
the enzyme under hypoxia. This suggests that PHDs function by a similar binding 
mechanism to the one described for other -ketoglutarate-dependent 
oxygenases such as FIH [30]. Molecular oxygen is the last substrate to bind the 
enzyme-substrate complex after the protein substrate and the co-substrate -
ketoglutarate bind. 
In order to get reliable results from a proteomic screen, it is important to find 
the right set up for the experiment. The idea that substrates can be trapped on 
the enzyme appeared to be the best option. Comparing binding to PHDs between 
hypoxic and normoxic conditions gave us a reasonable number of potential 
substrates to work with for each of the PHDs. Furthermore, samples 
overexpressing PHDs were compared to control transfected samples. In general 
more proteins were identified with these samples. However these proteins might 
not be substrates but rather proteins that show no differences in binding 
between normoxia and hypoxia such as regulators, inhibitors or scaffold 
proteins. All identified proteins should be validated as true interaction partners 
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of PHDs either by a second SILAC screen or by other assays (see following 
chapter). Even though SILAC is more specific than other non-quantitative 
proteomic approaches false positives still have to be ruled out. As with all 
proteomic approaches it should be kept in mind that identification of low 
abundant proteins in the presence of high abundant proteins is difficult as the 
signal of these low abundant proteins can be masked. This can lead to failure to 
identify some proteins as they are only identified above a certain threshold. 
Previously cut-offs to distinguish between background proteins and specific 
interactions have been chosen to be between 1.3-2fold difference in binding 
[116]. Here we chose a cut-off at 1.5. 
Overall, PHD3 seemed to be less expressed than other PHDs, which might 
account for the fact that there are less proteins identified to bind to PHD3 than 
to the other PHDs. -actin (or in some cases -actin) showed about a 2fold 
increase in binding to all three PHDs under hypoxia. It is one of the most 
consistent interactions using the substrate trap, but no interaction was found in 
any of the other conditions tested. It is difficult to distinguish between - and -
actin in this screen as these proteins are 98% identical. Other potential 
substrates we are particularly interested in are triosephosphate isomerase, 
malate dehydrogenase and lactate dehydrogenase, that were found to bind to 
PHD2 using the substrate trap and to PHD1 under hypoxia compared to the mock 
transfected control. As PHD1 was reported to be involved in metabolic signalling 
identifying PHD substrates involved in metabolism could shed some light on the 
underlying mechanism [79, 80]. 
Overall, potential new binding partners of PHDs were identified in this chapter 
using a quantitative proteomic approach. In the next chapter some of these 
potential interactions are validated. 
 
  
 
 
 
 
 
 
 
Chapter 4 – Validation of potential substrates 
Chapter 4, Validation of potential substrates   77 
4 Validation of potential PHD substrates 
4.1 Introduction 
In the previous chapter potential new PHD targets were identified in a proteomic 
screen however, these interactions have to be validated to rule out false 
positives. The most likely candidates as PHD substrates were identified as L-
lactate dehydrogenase, triosephosphate isomerase, fructose-bisphosphate 
aldolase and actin. The latter one had one of the highest scores in the SILAC 
screen whereas the first three were also identified in a second screen performed 
by Hendrik Daub. L-lactate dehydrogenase, triosephosphate isomerase and 
fructose-bisphosphate aldolase are metabolic enzymes involved in the molecular 
breakdown of glucose. PHD1 has been linked to be involved in metabolic 
regulation in skeletal muscles and hepatocytes, however substrates of PHD1 and 
pathways inducing these changes are unclear [79, 80]. Actin is part of the 
cytoskeleton that regulates processes such as locomotion, adhesion and cell 
shape. Polymerisation of monomeric (G-) actin into filaments (F-actin), turnover 
of these filaments as well as size of the intracellular G-actin pool is tightly 
regulated by different classes of actin-binding proteins [127]. Several lines of 
evidence link hypoxia to increased migration and tumour invasion [88, 91]. 
However not much is known about the influence of hypoxia on the actin 
cytoskeleton. In this chapter the interaction of PHDs and the above named 
proteins is tested. Furthermore the hydroxylation status of validated substrates 
and their intracellular localisation are investigated. 
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4.2 Results 
4.2.1 Validation of potential PHD targets 
4.2.1.1 Interaction of PHDs and specific metabolic enzymes 
Specific binding of potential PHD substrates was validated. Potential targets that 
were identified in the SILAC screen include the following metabolic enzymes: L-
lactate dehydrogenase, triosephosphate isomerase and fructose-bisphosphate 
aldolase. To validate binding between PHD1 and the above named metabolic 
enzymes, FLAG-tagged PHD1 was expressed in the melanoma cell line A375 or in 
the colon carcinoma cell line HCT116 followed by immunoprecipitation using anti 
FLAG antibodies. These experiments were performed with A375 cells as A375 
cells stably knocked-down for individual PHD isoforms were established in the 
lab, which can be used for functional studies [128]. Co-immunoprecipitations 
were performed under normoxia and under hypoxia followed by immunoblot 
analysis. Even though only L-lactate dehydrogenase and triosephosphate 
isomerase were identified as potential binding partners of PHD1, all three 
enzymes were tested for their ability to bind PHD1. 
As shown in Figure 4.1 L-lactate dehydrogenase, triosephosphate isomerase and 
fructose-bisphosphate aldolase are expessed under normoxia and hypoxia. L-
lactate dehydrogenase and fructose-bisphosphate aldolase are slightly 
upregulated under hypoxia as they are HIF target genes. However, no interaction 
was detected between PHD1 and these enzymes under the tested conditions. 
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Figure 4.1: Validation of binding between PHD1 and lactate dehydrogenase, 
triosephosphate isomerase and fructose-bisphosphate aldolase 
Co-immunoprecipitations were performed using FLAG-tagged PHD1 in A375 cells under 
normoxic or hypoxic conditions as indicated. 
 
To validate if either of the other PHDs interact with L-lactate dehydrogenase, 
triosephosphate isomerase and fructose-bisphosphate aldolase, co-
immunoprecipitations were performed under normoxia or hypoxia. FLAG-tagged 
PHD2 or PHD3 were overexpressed and immunoprecipitated using anti FLAG 
antibodies. L-lactate dehydrogenase and fructose-bisphosphate aldolase were 
identified as potential binding partners of PHD2 in the SILAC screen, but all 
three enzymes were tested for their ability to bind either PHD2 or PHD3. As 
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mentioned previously, overexpression of PHD3 can induce cell death [71], 
leading to less overexpression of PHD3 compared to other PHD isoforms.  
Chapter 4, Validation of potential substrates   81 
 
Figure 4.2: Validation of binding between PHD2 or PHD3 and lactate dehydrogenase, 
triosephosphate isomerase and fructose-bisphosphate aldolase 
(a) protein expression in total protein lysates of A375 cells (b) Co-immunoprecipitations 
were performed using FLAG-tagged PHD2 or PHD3 under normoxia or hypoxia. 
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Figure 4.2a shows the expression of these proteins in total cell lysates. PHD3 is 
slightly less expressed than PHD2 as was seen in previous experiments. As shown 
in Figure 4.2 none of these metabolic enzymes (L-lactate dehydrogenase, 
triosephosphate isomerase and fructose-bisphosphate aldolase) seem to interact 
with either PHD2 or PHD3. In conclusion, none of these potential substrates 
could be validated as targets of PHDs. 
 
4.2.1.2 Binding of actin and PHDs 
To validate the specific binding of actin to PHDs, co-immunoprecipitations 
followed by immunoblot analysis were performed in HCT116. In order to validate 
the interaction, FLAG-tagged PHDs were overexpressed in HCT116 cells and 
immunoprecipitated using anti FLAG antibodies. Firstly, all three PHDs (PHD1-3) 
were tested for their ability to bind actin under normoxic and hypoxic 
conditions.  
 
 
Figure 4.3: Validation of interaction between PHDs and actin in HCT116 cells 
Co-immunoprecipitations were performed using FLAG-tagged PHDs in HCT116 cells under 
normoxic or hypoxic conditions as indicated. 
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Little binding was detected under normoxia for all PHDs (lanes 1-3). Under 
hypoxia no binding was detected between PHD2 and actin (lane 5), PHD1 was 
found to bind only weakly (lane 4). However, PHD3 strongly bound actin in a 
hypoxia specific manner (lane 6). PHD3 appeared to be less expressed under 
hypoxia and therefore less immunoprecipitated, however actin still strongly 
binds to PHD3 under hypoxia whereas PHD1 and PHD2 are higher expressed 
under hypoxia than PHD3 and still show less binding. 
For further validation and to confirm specific interaction, co-
immunoprecipitations of overexpressed PHDs were also performed using the 
osteosarcoma cell line U2OS. U2OS cells were also used later on in this study 
when investigating the actin cytoskeleton as HCT116 cells do not have a 
distinctive actin cytoskeleton. 
 
 
Figure 4.4: Validation of interaction between PHDs and actin in U2OS cells 
Co-immunoprecipitations were performed using FLAG-tagged PHDs and FLAG-tagged B-
Raf in U2OS cells under normoxic or hypoxic conditions as indicated. 
 
The results shown in Figure 4.4 confirmed the previous results obtained HCT116 
cells. PHD3 is slightly less percipitated under normoxia than under hypoxia. 
Under normoxia all of the PHDs showed little to no binding to actin. Under 
hypoxia only PHD3 showed a strong interaction, PHD1 weakly interacted whereas 
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PHD2 did not bind to actin. FLAG-tagged B-Raf was used as a non-specific control 
and it did not interact with actin under any of the tested conditions. The 
interaction between actin and PHD3 shows the same pattern of substrate trap as 
found for the interaction of PHDs and HIF1. 
 
4.2.1.3 Binding to PHD3 under different oxygen conditions 
To validate the interaction of PHD3 and actin further and to make sure that the 
interaction is restricted to hypoxia, U2OS cells were incubated under normoxia 
or hypoxia or in the presence or absence of the PHD inhibitor DMOG, a non-
metabolisable -ketoglutarate derivative.  
 
 
Figure 4.5: Validation of specific binding of PHD3 and actin under hypoxia 
Co-immunoprecipitations were performed using FLAG-tagged PHD3 in U2OS cells under 
normoxia or hypoxia or in the presence of the PHD inhibitor DMOG 
 
As shown in section 4.2.1.2 the interaction between actin and PHD3 was specific 
for hypoxia, and only weak binding was detected under normoxia or using the 
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PHD inhibitor (Figure 4.5). Equal amounts of PHD3 percipitated. Similar results 
were obtained in the renal clear cell carcinoma cell line RCC4 (Figure 4.6). An 
additional treatment of TKG was added, a cell-permeable -ketoglutarate 
derivative which induces intracellular -ketoglutarate levels and reactivates 
PHDs even under hypoxia. 
 
 
 
Figure 4.6: Validation of specific binding of PHD3 and actin under hypoxia 
Co-immunoprecipitations were performed using FLAG-tagged PHD3 in RCC4 cells under 
normoxia or hypoxia, in the presence or absence of the PHD inhibitor DMOG or the PHD 
activator TKG 
 
As shown with the other cell lines PHD3 binds to actin specifically under hypoxia, 
but not under other conditions. The reasons for the changes of PHD3 expression 
under different conditions are unclear but could be due to PHD3 inducing cell 
death. 
Taken together these results showed specific binding between PHD3 and actin, 
which is stabilised under hypoxia. Therefore -actin was a good candidate for a 
PHD3 substrate. 
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4.2.2 Actin as PHD3 substrate 
Detection of hydroxy-proline is quite difficult. The preferred method these days, 
especially for lower abundant proteins is analysis by of a 16 Da mass shift of 
hydroxylated peptides by mass spectrometry. However one has to be careful to 
rule out an isobaric mass shift of oxidised methionine or other amino acids in 
these peptides.  
Based on studies of PHD-binding to HIF1, a conserved LXXLAP motif is thought 
to be the substrate-binding motif for prolyl hydroxylases [53]. However, this 
represents only a loose consensus, as mutations in all residues apart from the 
hydroxyl acceptor have been shown to be tolerated [54, 57]. We identified two 
putative binding motifs similar to the described LXXLAP motif in -actin around 
the prolyl residues at position 322 and 332. To investigate if either of these or 
any other prolyl residues in -actin were hydroxylated: actin fused to the Green 
Fluorescent Protein (GFP-actin) was overexpressed in human embryonic kidney 
HEK293 cells and then immunoprecipitated using anti GFP antibodies. HEK293 
cells were used to express large amounts of GFP-actin in order to be able to 
identify possible hydroxylation sites. The samples were separated on SDS-PAGE 
and stained with coomassie. The appropriate band was cut out and analysed by 
mass spectrometry (Figure 4.7). Mass spectrometric analyses were carried out by 
Richard Unwin (University of Manchester). 
 
Chapter 4, Validation of potential substrates   87 
 
 
Figure 4.7: -actin is hydroxylated at two specific proline residues (Pro70 and Pro322) 
GFP-actin was overexpressed in HEK293 cells and immunoprecipitated using anti GFP 
antibodies. (a) Samples were resolved on SDS-PAGE, stained with coomassie and the 
appropriate band was cut out and analysed by mass spectrometry. (b) Shown are the 
spectra of the two peptides that are hydroxylated at specific proline residues. (c) Structure 
of an actin monomer showing the positions of the hydroxylated residues. 
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Figure 4.7a shows the gel and the bands that were cut out from it to analyse 
hydroxylation sites. In lanes A-C different amounts of BSA were run on the gel to 
be able to compare how much GFP-actin was precipitated. 10% of the samples 
were run in lanes D and E. Two hydroxylation sites were identified in the 
following peptides which showed a 16 Da mass shift: YP(OH)IEHGIVTNWDDMEK 
(Pro70) and EITALAP(OH)STMK (Pro322) with P being the hydroxyl acceptor. The 
spectra are shown in Figure 4.7b. Pro322 lies within an IXXLAP sequence which 
resembles the LXXLAP binding motif described in the literature, although one of 
the leucines is replaced by the structurally very similar isoleucine. The second 
site of proline hydroxylation (Pro70) lies in a slightly less conserved IXXLXXP 
sequence. Figure 4.7c shows the crystal structure of an actin monomer and the 
position of the hydroxlated prolyl residues. 
 
4.2.3 Co-localisation of actin and PHD3 
To confirm the interaction of PHD3 and actin in cells, the intracellular 
localisation of all PHDs and their co-localisation with actin was investigated 
using immunofluorescence in U2OS cells as HCT116 cells were not suitable for 
analysis of the actin cytoskeleton. Firstly, overexpressed FLAG-tagged PHDs 
were detected with fluorescently labelled FLAG antibody and actin filaments 
with fluorescently labelled phalloidin, a toxin that specifically binds to and 
stabilises filamentous actin [123]. Co-staining was investigated under normoxia 
and hypoxia. 
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Figure 4.8: Colocalisation of PHDs and phalloidin-stained actin cytoskeleton 
FLAG-tagged PHDs were expressed in U2OS cells. After incubation in normoxia (a) or 
hypoxia (b) cells were stained with anti FLAG-FITC conjugated antibodies (green) and 
phalloidin-TRITC (red). Scale bars 20 µm. 
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As described previously, we confirmed that PHD1 is localised to the nucleus, 
PHD2 to the cytoplasm whereas PHD3 was found in both compartments (Figure 
4.8). The localisation of PHDs did not change under different oxygen conditions. 
None of the PHDs appeared to co-localise with the phalloidin-stained stress 
fibres either under normoxic or under hypoxic conditions.  
To address the question of whether PHDs co-localised with other forms of actin 
rather than larger actin patterns such as stress fibres, GFP-actin was used to 
visualise different actin population (Figure 4.9). FLAG-tagged PHDs and GFP-
actin were overexpressed, and the cells stained with fluorescent FLAG 
antibodies.  
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Figure 4.9: Colocalisation of PHDs and GFP-actin 
GFP-actin (green) as well as FLAG-tagged PHDs were overexpressed in U2OS cells grown in 
normoxia (a) or hypoxia (b). FLAG-tagged PHDs were stained with anti FLAG-Cy3 antibodies 
(red). Scale bars 20 µm. 
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PHD1 did not co-localise with GFP-actin. PHD2 and PHD3 are both cytoplasmic 
proteins, but only PHD3 appeared to show some co-localisation with GFP-actin 
whereas PHD2 did not show any co-localisation (Figure 4.9). Under conditions of 
low oxygen a rearrangement of the actin cytoskeleton was found.  
To investigate if this actin rearrangement is dependent on oxygen levels, cells 
were grown under the following oxygen conditions: normoxia, hypoxia or re-
oxygenation after incubation under hypoxia. 
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Figure 4.10: Actin rearrangement under different oxygen conditions when PHD3 is 
overexpressed 
GFP-actin (green) as well as FLAG-tagged PHD3 were overexpressed in U2OS cells. FLAG-
tagged PHD3 was stained with anti FLAG-Cy3 antibodies (red). Cells were incubated under 
normoxia, hypoxia or reoxygenated for 30 minutes after incubation under hypoxia. Scale 
bars 20 µm. (b) Antibody control for FLAG-Cy3 in mock transfected cells. 
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Figure 4.10 shows that actin stress fibres disappear under hypoxia, but at least 
partially reappear after reoxygenation. Our results might suggest that PHD3 
binds to smaller actin formations, visualised as diffuse staining, rather than 
larger actin patterns such as stress fibres. However it is not entirely clear from 
these experiments which states of actin might colocalise with PHD3. 
Investigating this further, co-immunoprecipitations followed by immunoblot 
analysis were performed in HCT116 and U2OS cells. FLAG-tagged PHD3 was 
overexpressed in HCT116 or U2OS cells, which were treated with either 
latrunculin A or cytochalasin D, two different drugs that disrupt the actin 
cytoskeleton, and immunoprecipitated using anti FLAG antibodies. 
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Figure 4.11: Binding of actin and PHD3 after treatment with actin drugs 
(a) Immunostaining of the actin cytoskeleton after treatment with cytochalasin D or 
latrunculin A. (b-d) Co-immunoprecipitations were performed using FLAG-tagged PHD3 in 
HCT116 cells (b) or U2OS cells (c-d) under hypoxia. Cells were treated with cytochalasin D 
or latrunculin A as indicated. 
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In Figure 4.11b co-immunoprecipitations were performed under normoxia and 
hypoxia using HCT116 cells that were treated with cytochalasin D, a drug that 
disrupts the actin cytoskeleton by binding to the (+) end of the filaments and 
therefore inhibiting binding of further actin monomers [121]. No binding was 
detected under normoxia. Under hypoxia binding between PHD3 and actin was 
increased when cells were treated with cytochalasin D. 
In Figure 4.11c-d co-immunoprecipitations were performed under hypoxic 
conditions using U2OS cells that were treated with cytochalasin D or latrunculin 
A. Latrunculin A disrupts the actin cytoskeleton by binding to actin monomers 
inhibiting the growth of the filaments [120]. In Figure 4.11c an increase in 
binding between actin and PHD3 is observed when cells are treated with 
cytochalasin D. However a decrease in binding is found when cells are treated 
with latrunculin A wich was also confirmed in Figure 4.11d. Figure 4.11a shows 
the actin cytoskeleton after treatment with cytochalasin D and latrunculin A. 
 
4.3 Conclusions 
In the previous chapter potential substrates of PHDs were identified in a 
quantitative proteomic screen. The interaction between PHDs and some of these 
potential targets were further validated. First, the binding of metabolic enzymes 
such as L-lactate dehydrogenase, triosephosphate isomerase and fructose-
bisphosphate aldolase to PHDs was analysed as these protein were also identified 
to have potential hydroxylation sites. None of these metabolic enzymes could be 
confirmed as substrates of PHDs under the conditions tested. The ratios for 
binding between of L-lactate dehydrogenase or fructose-bisphosphate aldolase 
to PHD2 probably did not show enough difference to be genuine substrates. 
These low ratios coincided with low peptide counts. Binding between L-lactate 
dehydrogenase or triosephosphate isomerase and PHD1 was identified in the 
SILAC screen when comparing PHD1 transfected samples with control transfected 
samples under hypoxia and not with the substrate trap. This could confirm that 
the substrate trap is the best indication for binding between PHDs and their 
substrates. 
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Subsequently the interaction between actin and PHDs was validated. Using the 
substrate trap actin was identified to potentially bind to all PHDs. In all cases 
actin was identified with ratios >1.5 and with high peptide counts. Validating the 
interaction we showed that PHD3 was the only PHD isoform that strongly binds 
actin specifically under hypoxic conditions in co-immunoprecipitation 
experiments. Weak binding to PHD1 was found in immunoprecipitations, but 
could not be confirmed in immunofluorescence experiments. Therefore it is 
likely that the weak interaction found in immunoprecipitations is due to the loss 
of intracellular compartments during the experiment rather than the interaction 
of PHD1 with nuclear actin. Subsequently -actin was found to be hydroxylated 
at Pro70 and Pro322, suggesting that it is indeed a substrate of prolyl 
hydroxylases. These prolyl residues lie within sequences resembling the LXXLAP 
binding motif described in the literature for HIF1 [53], even though one or both 
leucine residues are replaced by the structurally similar isoleucine. However so 
far it could not be proven that this hydroxylation is dependent on PHD3. As 
hydroxylated and non-hydroxylated peptides have the same retention time in 
the mass spectrometer, it can be estimated that about 10% of actin is 
hydroxylated. In immunofluorescence experiments, co-localisation of PHD3 and 
actin was observed confirming the specific interaction of PHD3 and actin. 
However, PHD3 did not co-localise with larger actin patterns such as stress fibres 
but rather with smaller, more diffuse states of actin. None of the other PHDs co-
localises with phalloidin-stained stress fibres or with GFP-actin. Furthermore, 
the actin cytoskeleton appeared to change under hypoxia, especially when PHD3 
was overexpressed. A normoxic phenotype could be recovered after 
reoxygenation. To investigate the possibility that PHD3 rather binds to 
monomeric actin than actin filaments, immunoprecipitations were performed in 
the presence of actin drugs that disrupt the actin cytoskeleton and therefore 
increasing the intracellular G-actin concentration. Cytochalasin D binds to the 
(+) end of filaments inhibiting further addition of monomers, therefore 
increasing the concentration of free monomers. Treatment with cytochalasin D 
was shown to increase binding between actin and PHD3 in hypoxic conditions as 
would be expected if PHD3 binds to monomeric forms of actin. Latrunculin A 
binds to the actin monomers inhibiting their binding to actin filaments. 
Treatment of cells with latrunculin A decreased binding between actin and PHD3 
in hypoxic conditions compared to untreated samples. Both drugs induce the 
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intracellular concentration of actin monomer, but as described above they work 
by different mechanisms. Given the differences how these two drugs were shown 
to bind to actin it could give an insight to where PHD3 binds to actin. Increasing 
actin monomers in the cells increased interaction, however binding seems to be 
inhibited by latrunculin A, possibly by competing with PHD3 for binding to the 
monomers. Latrunculin A binds to a region near the ATP binding pocket of actin 
and could therefore compete the binding of PHD3 hydroxylating Pro70 which is 
also near the ATP binding pocket. 
In this chapter one of the potential substrates identified in a quantitative 
proteomic approach could be confirmed to interact with PHD3 whereas others 
could not be validated. This proves the importance of validating the results from 
a proteomic screen to rule out false positives. We showed the specific 
interaction between PHD3 and actin and identified a new post-translational 
modification of actin, the hydroxylation of two specific prolyl residues. However 
it is still unclear if this hydroxylation is due to the function of PHD3 and changes 
under conditions in which PHD3 is inhibited. In the next chapter the biological 
function of the interaction between -actin and PHD3 was analysed. 
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5 The biological role of actin hydroxylation 
5.1 Introduction 
In the previous chapter -actin was found to specifically interact with PHD3 and 
to be hydroxylated at two specific proline residues. However the biological 
function of this interaction remains unclear. Hypoxia was linked to an increase in 
cell migration and tumour invasion however signalling pathways involved as well 
as the impact on the actin cytoskeleton under these conditions are mostly 
unkown [88, 91]. In this chapter the effects of PHD3 activity on the actin 
cytoskeleton, cell migration and invasion are investigated. 
 
5.2 Results 
5.2.1 Loss of PHD3 activity leads to rearrangement of the actin 
cytoskeleton 
Possible changes in the actin cytoskeleton under low oxygen conditions that 
were found when validating the binding between PHD3 and actin (chapter 4) 
were further investigated. To visualise different actin populations the following 
tools were used: either GFP-actin was overexpressed in cells to show G- as well 
as F-actin, or cells were stained with fluorescently labelled phalloidin to show F-
actin within stress fibres or with fluorescently labelled DNAse1 to look at G-actin 
[124]. The actin cytoskeleton was investigated under normoxic conditions, using 
pharmacological PHD inhibitors (DMOG), under hypoxia and adding a cell-
permeable -ketoglutarate derivative to reactivate PHDs under hypoxia (TKG) 
[36].  
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Figure 5.1: Rearrangement of the actin cytoskeleton following inhibition of PHDs 
(a) GFP-actin (green) was overexpressed in U2OS cells, which were co-stained with 
fluorescent phalloidin (red). Cells were grown under normoxic and hypoxic conditions and 
treated with either DMOG or TKG as indicated. (b) Intracellular F-actin levels were 
quantified by labelling actin filaments with saturating amounts of phalloidin-TRITC. Cells 
were treated as in panel a. F-actin content is shown as comparison to untreated samples 
measured on the same day (means ± SEM). Each condition is a representation of 9 
individual samples. P-values as compared to untreated nomoxia: normoxia + DMOG 0.0379, 
hypoxia 0.0340, hypoxia + TKG 0.9156. (c) Cells were treated as indicated and actin 
filaments were stained with phallodin-TRITC (red) and actin monomers with DNAse1-
Alex488 (green). Scale bars 20 µm. (d) Quantification of G-actin levels. Images in panel c 
were used to quantify intracellular G-actin levels. The intensity of DNAse1-staining per cell 
was analysed using ImageJ. Intensities per cell are shown as comparison to untreated 
normoxic samples. 
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Firstly, GFP-actin was overexpressed in U2OS cells and stained with fluorescent 
phalloidin (Figure 5.1a). Under conditions, where PHDs are inhibited, namely the 
addition of DMOG and hypoxia, fewer stress fibres and a more diffuse cytosolic 
actin staining was visible. A normoxic phenotype can be restored when PHDs are 
reactivated using the cell-permeable -ketoglutarate derivative under hypoxia 
(TKG). In a second approach and to confirm these results in an endogenous 
system, U2OS cells were stained with phalloidin and DNAseI (Figure 5.1c). 
DNAseI staining increased in conditions where PHDs were inactive confirming the 
data using GFP-actin. Reactivation of PHDs led to a similar DNAseI staining level 
as seen under normoxia. Images like those shown in Figure 5.1c were used to 
quantify intensities per cell of DNAseI-staining using ImageJ (Figure 5.1d). In 
Figure 5.1a differences in larger actin patterns such as stress fibres are visible. 
Linked to this observation, possible changes in intracellular F-actin levels were 
quantified using an assay described by Machesky and Hall [125]. Briefly, cell 
extract was labelled with a saturating amount of phalloidin-TRITC. The amount 
of bound phalloidin was quantified after its extraction by fluorescence emission 
and normalised for its protein content. The data are shown as a percentage 
compared to untreated cells processed on the same day. Inhibition of PHDs led 
to a decrease in intracellular F-actin content. Reactivation of PHDs under 
hypoxia with TKG brought the F-actin content back to normoxic levels (Figure 
5.1b). 
To investigate which of the PHDs was important for this actin cytoskeleton 
rearrangement, PHDs were inhibited by knocking them down individually.  
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Figure 5.2: Rearrangement of the actin cytoskeleton is dependent on PHD3 activity. 
(a) Immunoblot analysis to confirm efficient knockdown of each of the PHDs after transient 
transfection of short hairpin RNA plasmids into U2OS cells. Knockdown was confirmed on 
FLAG-tagged PHDs and on endogenous proteins. (b) Normoxic U2OS cells, in which each of 
the PHDs was knocked-down individually, were stained with GFP-actin (green) and 
phalloidin-TRITC (red). (c) Quantification of F-actin levels by measuring fluorescent 
emission after labelling actin filaments with phalloidin-TRITC. F-actin content is shown as 
comparison to samples transfected with shControl measured on the sam day (means ± 
SEM). Each condition is a representation of 9 individual samples. P-values as compared to 
shControl: shPHD1 0.6585, shPHD2 0.9296, shPHD3 0.0304. (d) Endogenous actin was 
stained with phalloidin-TRITC (red) and DNAseI-Alexa488 (green). Scale bars 20 µm. (e) 
Images in panel d were used to quantify intracellular G-actin levels. The intensity of DNAseI-
staining per cell was analysed using ImageJ. Intensities per cell are shown as comparison 
to untreated shControl cells. 
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The knockdown of each PHD was confirmed by immunoblot analysis (Figure 
5.2a). Using GFP-actin and phalloidin staining in immunofluorescence 
experiments we found that the reduction of PHD1 or PHD2 under normoxia did 
not have an effect on the actin cytoskeleton, only the reduction of PHD3 led to 
loss of stress fibres similar to hypoxia or pharmalogical inhibition of PHDs (Figure 
5.2b). These results were confirmed by DNAseI and phalloidin staining (Figure 
5.2d). The knockdown of PHD1 or PHD2 only had minor effects on the actin 
cytoskeleton. However, the G-actin staining increased to a similar extent as 
pharmacological inhibition of PHDs when PHD3 was knocked down. 
Quantification of the F-actin content showed a decrease in F-actin when PHD3 
was lost, whereas loss of PHD1 or PHD2 did not have an effect on the F-actin 
levels (Figure 5.2c). Images in Figure 5.2c were used to quantify intensities per 
cell of DNAseI-staining using ImageJ (Figure 5.2d). 
Similar results were obtained with A375 cells. Under conditions in which the 
PHDs were inhibited the intracellular F-actin content was decreased, whereas 
the G-actin content increased. This was shown by both immunofluorescence as 
well as quantitation of the F-actin level using phalloidin (Figure 5.3). GFP-actin 
was overexpressed in A375 cells and cells were stained with phalloidin (Figure 
5.3a). Fewer stress fibres were visible when PHDs are inhibited as seen in U2OS 
cells. Using TKG to reactivate PHDs under hypoxia a normoxic phenotype can 
be restored. These results were confirmed in an endogenous system staining 
A375 cells with phalloidin and DNAseI (Figure 5.3c). DNAseI staining increased 
when PHDs were inactive. Reactivation of PHDs with TKG decreased DNAseI 
levels to normoxic levels. Samples stained with DNAseI were used to quantify 
intensities per cell using ImageJ (Figure 5.3d). Changes in intracellular F-actin 
levels were also quantified as described above. A decrease in F-actin content 
was detected when PHDs were inhibited. A normoxic phenotype was restored 
when PHDs were reactivated by TKG under hypoxia (Figure 5.3b). 
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Figure 5.3: Actin rearrangement in A375 cells is dependent on PHD activity. 
A375 cells were incubated under normoxic or hypoxic conditions for 24 hours and treated 
as indicated. (a) Cells overexpressing GFP-actin (green) were co-stained with phalloidin-
TRITC (red). (b) Quantification of endogenous F-actin levels. F-actin content is shown as 
comparison to normoxic untreated samples measured on the same day (means ± SEM). 
Each condition is a representation of 9 individual samples. P-values as compared to 
untreated normoxia: normoxia + DMOG 0.0032, hypoxia 0.0013, hypoxia + TKG 0.2856. (c) 
Actin filaments were stained with phalloidin-TRITC (red) and actin monomers with DNAseI-
Alexa488 (green). Scale bars 20 µm. (d) Quantification of G-actin levels. Images like in panel 
c were used to quantify intracellular G-actin levels. The intensity of DNAseI-staining per cell 
was analysed using ImageJ. Intensities per cell are shown as comparison to untreated 
normoxic samples. 
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These experiments were repeated in A375 cells stably knocked-down for 
individual PHD isoforms. For each of the PHD isoforms two stable clones were 
used. The stable cell lines were established by Dan Tennant [128]. Levels of 
achieved knockdown were identified by quantification of mRNA levels as 
described by Dan Tennant [128] (Figure 5.5). 
 
Abbildung 5.4: Assessment of stable PHD knockdown clones as shown by Dan Tennant 
[128] 
mRNA expression levels for two independent clones relative to -actin and control 
(shControl) clone for (a) PHD1, (b) PHD2 and (c) PHD3. 
Chapter 5, The biological role of actin hydroxylation  107 
Then, the actin cytoskeleton of A375 cells stably knocked-down for PHD3 was 
investigated. 
 
 
 
Figure 5.5: Actin rearrangement in A375 cells is dependent on PHD3 activity. 
(a) A375-derived stable PHD3 knockdown clones overexpressing GFP-actin (green) were co-
stained with phalloidin-TRITC (red). (b) Quantification of endogenous F-actin levels. F-actin 
content is shown as comparison to a shControl cell line measured on the same day (means 
± SEM). Each condition is a representation of 6 individual samples. P-values as compared to 
shControl cell line: shPHD3 clone 1 0.0247, shPHD3 clone 2 0.0161. (c) Actin filaments were 
stained with phalloidin-TRITC (red) and actin monomers with DNAseI-Alexa488 (green). 
Scale bars 20 µm. (d) Quantification of G-actin levels. Images like in panel c were used to 
quantify intracellular G-actin levels. The intensity of DNAseI-staining per cell was analysed 
using ImageJ. Intensities per cell are shown as comparison to untreated normoxic samples. 
 
Two stable PHD3 knockdown clones of A375 cells showed an increase in G-actin 
using GFP-actin or DNAseI and phalloidin staining compared to a control cell line 
(Figure 5.5a+c). A decrease in F-actin content was found in these cells as shown 
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in a quantitative approach (Figure 5.5b). The actin cytoskeleton in these cells 
was less prominent than in U2OS or A375 cells shown before. Other cell lines 
derived from A375 cells with stable knockdowns of either PHD1 or PHD2 were 
also analysed for their actin organisation in immunofluorescence experiments 
(Figure 5.6).  
 
 
Figure 5.6: Actin organisation in A375-derived knock down cells 
A375-derived stable PHD1 or PHD2 knockdown clones overexpressing GFP-actin (green) 
were co-stained with phalloidin-TRITC (red). (c) Actin filaments were stained with phalloidin-
TRITC (red) and actin monomers with DNAseI-Alexa488 (green). Scale bars 20 µm. (c) 
Quantification of G-actin levels. Images like in panel c were used to quantify intracellular G-
actin levels. The intensity of DNAseI-staining per cell was analysed using ImageJ. 
Intensities per cell are shown as comparison to untreated normoxic samples. 
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Two stable clones of each PHD1 or PHD2 knockdown cell lines were analysed in 
immunofluorescence experiments. No changes in the actin cytoskeleton were 
found compared to a control cell line using GFP-actin and phalloidin staining or 
when using DNAseI and phalloidin staining (Figure 5.6a+b). Intensities in DNAseI 
staining were quantified but no significant differences could be found (Figure 
5.6c). Results for the quantification of intracellular F-actin levels were 
inconclusive. Different levels were observed when compared to different control 
cells. The actin cytoskeleton in these cells is less pronounced than in U2OS or 
parental A375 cells and DNAseI staining stained the nucleus more than in above 
experiments. 
Taken together, the results of U2OS and A375 cells showed a rearrangement of 
the actin cytoskeleton when PHDs are inhibited either by hypoxia or by 
pharmacological inhibitors such as DMOG. Intracellular F-actin decreased under 
these conditions to levels similar to those observed when using drugs that 
disrupt actin filaments. At the same time intracellular G-actin levels were 
increased under the same conditions. This phenotype was reversed when PHDs 
were reactivated under hypoxia. The hypoxia-induced actin reorganisation is 
mediated by the decrease of PHD3 as only the reduction of PHD3 levels but not 
the reduction of other PHDs led to the same phenotype. 
 
5.2.2 Loss of PHD3 activity leads to increased migration and 
invasion 
It has been shown that some pathways involved in migration and invasion can be 
regulated by hypoxia [91]. To study whether actin rearrangement under hypoxia 
resulted in different behaviour in cell migration, wound healing scratch assays 
were performed. U2OS cells were grown until they formed a confluent 
monolayer before a wound was scratched into this monolayer using a pipette tip 
and cell movement into the wound was monitored.  
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Figure 5.7: Cell migration is dependent on PHD activity 
(a) monolayers of U2OS cells were scratched by a pipette and left to migrate into the gap in 
the presence or absence of DMOG. Bright field images were taken at time points indicated. 
(b) Wound closure was performed as in panel a at the indicated conditions and cells were 
tracked by time-lapse microscopy. The single cell tracking device of ImageJ was used to 
analyse distance and velocity of cell migration. Data shown is the analysis of representative 
experiment (a least 30 cells per condition; means ± SEM). P-values as compared t untreated 
normoxia: normoxia + DMOG 0.0025, hypoxia 0.0112, hypoxia + TKG 0.2114. 
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Cells migrated faster in this 2D migration assay when PHDs were inhibited either 
by hypoxia or DMOG (Figure 5.7) as was shown in bright field images taken at 
different time points as well as by quantification using the single cell tracking 
device of ImageJ. Shown are distance plots as well as velocities of cells. 
Reactivating PHDs under hypoxia using cell permeable TKG derivative resulted 
in a decreased velocity of cells to levels similar to normoxia.  
These migration assays were repeated under normoxia after having knocked 
down each PHD individually (Figure 5.8).  
 
 
 
Figure 5.8: Cell migration is dependent on PHD3 activity 
PHDs were knocked down individually in U2OS cells and cell migration assays were 
performed under normoxic conditions. P-values as compared to shControl: shPHD1 0.1957, 
shPHD2 05791, shPHD3 0.0261. 
 
Decrease of PHD1 or PHD2 did not change the velocity of cells. However, the 
decrease of PHD3 resulted in an increase in velocity similar to that observed 
under hypoxia. It is currently accepted that an optimal G- to F-actin ratio is 
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required for maximal cell motility and invasiveness. Indeed, efficient cell 
movement requires actin polymerization, but high levels of F-actin and stress 
fibres can oppose cell migration by increasing cell adhesion. As cell migration is 
dependent on a fine balance of the intracellular G- to F-acin levels, it is hard to 
predict how changes in the actin cytoskeleton influence cell migration, wound 
healing scratch assay were performed using different concentrations of 
latrunculin A, a drug that disrupts the actin cytoskeleton (Figure 5.9). 
 
 
Figure 5.9: Dependency of cell migration on ability of actin to polymerise 
Wound closure was performed under normoxia and U2OS cells were treated with different 
concentrations of latrunculin A. Cells were tracked by time-lapse microscopy. The single 
cell tracking device of ImageJ was used to analyse distance and velocity of cell migration. 
Data shown is the analysis of a representative experiment (at least 20 cells per condition; 
means ± SEM). P-values compared to untreated samples: 10 nM latA 0.0004, 50 nM latA 
0.0018, 100 nM latA <0.0001, 300 nM latA <0.0001. 
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Low doses of latrunculin A enhanced cell motility, whereas higher concentration 
of latrunculin A led to a decrease in migration until cell migration was halted. 
This shows that a fine balance of G- to F-actin and the amount of polymerisable 
actin in the cells are important for cell migration. This indicates that fine 
changes in the G- to F-actin ratio regulate cell motility. As a proof of principle 
this titration was only performed with latrunculin A, however similar results 
would be expected for a titration using cytochalasin D. 
These wound healing scratch assays were also performed with A375 cells (Figure 
5.10). Although A375 cells migrated slower than U2OS cells in this 2D assay, they 
showed similar results to those using U2OS.  
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Figure 5.10: Distance and velocity analysis of A375 cells in wound healing scratch assays 
Wound closure was tracked by time-lapse microscopy. The single cell tracking device of 
ImageJ was used to carry out analyses. Data shown is the analysis of a representative 
experiment (at least 30 cells per condition; mean ± SEM). A375 and stable clones of PHD3 
knockdown cells were treated as indicated. P-values as compared to untreated normoxia: 
normoxia + DMOG 0.0089, nomroxia shPHD3 0.0011, hypoxia 0.0015, hypoxia + TKG 
0.5679. 
 
When incubated under hypoxia or with DMOG, A375 cells migrated faster. This 
was also observed in cells with stable PHD3 knock down. A normoxic phenotype 
was restored in hypoxic cells when PHDs were reactivated. The migration of 
stable PHD1-2 knockdown A375-derived cells was analysed as well (Figure 5.11). 
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Two clones of each knockdown were used. A375-derived PHD1 or PHD2 stable 
knockdown cells did not show any significant differences in migration compared 
to a control cell line. Cells in this experiment appeared to migrate a little slower 
than A375 cells in previous experiments. 
 
 
Figure 5.11: Distance and velocity analysis of A375-derived PHD1-2 knockdown cells in 
wound healing scratch assays 
Wound closure was tracked by time-lapse microscopy. The single cell tracking device of 
ImageJ was used to carry out analyses. Data shown is the analysis of a representative 
experiment (at least 30 cells per condition; mean ± SEM). 
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The next question was whether this increased migration in a 2D environment 
would also lead to an increase in invasion in a 3D model. The ability of cells to 
invade into a matrigel plug towards a chemotactic gradient was assessed under 
either normoxic or hypoxic conditions. U2OS cells were found to invade poorly 
into the matrigel plug, so A375 cells were used for this assay. Invasion assay 
were performed by Patrick Caswell (Beatson Institute for Cancer Research). 
 
 
 
Figure 5.12: Invasion of A375 cells and derived shPHD3 stable clones into matrigel 
Invasion of A375 cells and derived shPHD3 stable clones inot matrigel was analysed 
microscopically under normoxic and hypoxic conditions. (a) Shown are microscopic focal 
planes at defined distances into the matrigel. Cells invading further than 45 m were 
considered invasive. Data shown are representative results of confocal sections (every 15 
m) throughout the matrigel plug as well as (b) the quantitative analysis of 6 individual 
samples (means ± SEM). 
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Compared to invasion under normoxia, A375 cells invaded further under hypoxia 
(Figure 5.12). The reduction of PHD3 increased invasion under normoxia 
compared to a control cell line as well. Taken together, these results showed 
that hypoxia-induced cell migration and invasion can be mimicked by decreasing 
PHD3 expression levels.  
It would have been interesting to repeat these invasion assays in the presence of 
drugs influencing PHD activity such as DMOG or TKG or influencing the actin 
cytoskeleton such as latrunculin A or cytochalasin D however, it was difficult to 
find the right conditions for treatment of the cells with these drugs over the 
period of time the assay was running. 
 
5.2.3 Mutation of Pro70 and Pro322 effects the actin cytoskeleton 
and cell migration 
To investigate the importance of residues Pro70 and Pro322 of -actin in 
cytoskeleton rearrangement induced by PHD3 reduction or hypoxia one or both 
of these residues were mutated to alanine in a GFP-actin expression vector. 
These GFP-tagged wildtype and mutant constructs were overexpressed in U2OS 
cells, while concomitantly knocking down endogenous actin using different siRNA 
sequences, which targeted the 3’UTR sequence of actin.  
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Figure 5.13: Immuoblot analysis confirming the knockdown of endogenous actin and 
expression of wildtype GFP-actin and its mutants 
Immunoblot analysis was used to confirm the knockdown of endogenous actin as well as 
the rescue of cells with the exogenously expressed GFP-actin. 
 
The knock down of endogenous actin was confirmed by immunoblot analysis 
(Figure 5.13). The actin cytoskeleton was investigated by overexpressing these 
GFP-tagged plasmids and staining the actin filaments with phalloidin.  
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Figure 5.14: Pro70 and Pro322 of -actin regulate the state of actin 
(a) Wildtype (wt) GFP-actin or the indicated proline mutations on GFP-actin fusion proteins 
were expressed in U2OS cells while endogenous actin was knocked down by two different 
siRNA. Cells were co-stained with phalloidin-TRITC (red). Scale bar 20 m. (b) Quantification 
of endogenous F-actin levels. F-actin content is shown as comparison to cells 
overexpressing wildtype GFP-actin measured on the same day (means ± SEM). Each 
condition is a representation of 10 individual samples. P-values as compared to wildtype 
GFP-actin: P70A 0.0536, P322A 0.0178, P70A/P322A 0.0004 
 
Mutation of either Pro70 or Pro322 only had a minor effect on the organisation of 
filamentous actin compared to GFP-actin whereas mutation of both of these 
residues resulted in a significant decrease of actin filaments (Figure 5.14). The 
results were similar with both siRNAs for endogenous actin tested. This could 
also be quantified using the phalloidin-binding assay (Figure 5.14b). The 
influence of these actin mutants on cell migration was investigated in wound 
healing scratch assays.  
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Figure 5.15: Pro70 and Pro322 of -actin regulate cell migration 
The effect of actin mutants on cell migration was analysed by time-lapse miscoscopy under 
normoxic conditions using U2OS cells. Distance plots and velocity of cells are shown. Data 
shown is the analysis of a representative experiment (at least 30 cells per conditions; 
means ± SEM). P-values as compared to wildtype GFP-actin: P70A <0.001, P322A <0.0001, 
P70A/P322A <0.0001. 
 
A significant increase in migration was found when overexpressing either of the 
single mutants compared to the wildtype GFP-actin whereas the double mutant 
showed a greater, additive effect, which correlates with a further increase in 
velocity (Figure 5.15). Taken together these results suggest that both of these 
prolyl residues are important for actin cytoskeleton rearrangement and cell 
migration. It would be interesting to follow up these results with matrigel 
invasion assays however these assays have not been done yet. 
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5.2.4 Effect of HIF1 and HIF2 on the actin cytoskeleton and cell 
migration 
To investigate if these changes in organisation of actin are dependent on HIF 
activity HIF mutants were overexpressed in U2OS cells. The two proline residues 
(Pro402 and Pro564 in HIF1/Pro405 and Pro531 in HIF2) as well as the 
asparagine residue (Asp803 in HIF1) were mutated to alanine, preventing these 
HIF proteins from hydroxylation and subsequent degradation therefore these 
mutants are constantly active. 
The overexpression of HIF mutants was confirmed by immunoblot analysis 
(Figure 5.16a). Using GFP-actin and phalloidin staining in immunofluorescence 
experiments overexpression of HIF mutants only had minor effects on the actin 
cytoskeleton under normoxia (Figure 5.16b). Similar results were obtained with 
DNAseI and phalloidin staining (Figure 5.16d+e). These results were also 
quantified using the images from Figure 5.16d. The results obtained using 
immuofluorescence were confirmed when intracellular F-actin levels were 
quantified (Figure 5.16c). These results indicate that changes in the actin 
cytoskeleton are independent on HIF levels and activity. 
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Figure 5.16: Effect of HIF1 and HIF2 on actin cytoskeleton 
(a) Immunoblot analysis to confirm expression of HIF1and HIF2triple mutants (HIF1TM 
or HIF2TM) after transient transfection into U2OS cells. (b) Normoxic U2OS cells 
overexpressing HIF mutants, were stained with GFP-actin (green) and phalloidin-TRITC 
(red). (c) Quantification of F-actin levels by measuring fluorescent emission after labelling 
actin filaments with phalloidin-TRITC. F-actin content is shown as comparison to samples 
transfected with shControl measured on the same day (means ± SEM). Each condition is a 
representation of 6 individual samples. P-values as compared to a control sample: HIF1TM 
0.8324, HIF2TM 0.2229. (d) Endogenous actin was stained with phalloidin-TRITC (red) and 
DNAseI-Alexa488 (green). Scale bars 20 µm. (e) Images in panel d were used to quantify 
intracellular G-actin levels. The intensity of DNAseI-staining per cell was analysed using 
ImageJ. Intensities per cell are shown as comparison to untreated control cells. 
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The next question was whether cell migration is increased in a HIF dependent 
mechanism. HIF mutants were overexpressed in U2OS cells and wound closure 
was monitored by time-lapse microscopy. 
 
 
 
Figure 5.17: Effect of HIF triple mutants on cell migration 
Monolayers of U2OS cells were scratched by pipettes and left to migrate into the gap. Cells 
were tracked by time-lapse microscopy. The single cell tracking device of ImageJ was used 
to analyse distance and velocity of cell migration. Data shown is the analysis of 
representative experiment (a least 30 cells per condition; means ± SEM). P-values as 
compared to control cells: HIF1TM 0.5249, HIF2TM 0.0624. 
 
Overexpression of HIF mutants did not lead to significant changes in cell 
migration compared to control cells. Even though overexpression of HIF2TM led 
to an increase in migration, the changes were not statistically significant. 
Overall, changes in the actin cytoskeleton as well as cell migration appear to be 
induced by a HIF-independent mechanism. 
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5.3 Conclusions 
Hypoxia-induced changes in the actin cytoskeleton were found to be dependent 
on PHD3 expression levels as knock down of PHD3 was sufficient to increase the 
intracellular G- to F-actin ratio as was shown by immunofluorescence as well as 
in a quantitative approach. Using immunofluorescence, loss of stress fibres as 
well as an increase in G-actin was shown, whereas the quantitative approach 
showed loss of phalloidin-stained actin filaments. Subsequently, hypoxia-induced 
cell migration and invasion were shown to be dependent on PHD3 levels as well. 
All these experiments were performed using U2OS cells, A375 cells and A375-
derived stable PHD knock down cells. Although A375 cells, especially the stable 
knock down cells, show a less distinct actin cytoskeleton and migrate slower in 
wound healing scratch assays similar results were obtained in all cell lines. As 
the width of the wound varied the single cell tracking device of ImageJ was used 
to analyse these assays. Changes in the distance plots are less obvious than 
changes in graphs for velocity where a 20-30% change is found. Using U2OS cells 
it could be shown that the rate of cell migration is dependent on the 
intracellular G- to F-actin ratio. Increasing amounts of the actin disrupting drug 
latrunculin A led to an increase in cell migration until migration stops at higher 
concentration of the drug. Both hydroxylated prolyl residues in actin (Pro70 and 
Pro322) appear to be important for the function described as mutation of these 
residues to alanine led to rearrangement of the actin cytoskeleton and increased 
cell migration. Single mutations appeared to have some effect, but the mutation 
of both prolyl residues had a greater, additive effect on the actin cytoskeleton 
and cell migration.  
To reveal if PHD3-dependent actin cytoskeleton rearrangement and migration is 
dependent on HIF activity, non-degradable and therefore constantly active 
HIF1 and HIF2 mutants used to investigate their effect on the actin 
cytoskeleton and cell migration. PHD3-dependent changes in the actin 
cytoskeleton and migration were found to be independent on HIF1 and HIF2 as 
overexpression of HIF mutants did not change the actin cytoskeleton as was 
shown by immunofluorescence and in a quantitative approach and did not 
increase cell migration.  
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In this chapter a new link between oxygen-sensing pathways and hypoxia-
induced cell migration was found, in which PHD3 appears to signal directly to 
components of the cytoskeleton. However the underlying mechanisms how 
hydroxylation of actin leads to rearrangement of the actin cytoskeleton and 
increased cell migration and invasion still remain to be elucidated. 
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6 General summary and outlook 
Here we show a new link between oxygen-sensing pathways and hypoxia-induced 
cell migration. We describe a HIF-independent pro-invasive pathway, in which 
PHD3 activity affects the actin cytoskeleton. We identified the specific 
interaction between PHD3 and actin and identified a new post-translational 
modification of actin, the hydroxylation of two specific prolyl residues. A 
number of post-translational modification of actin were shown previously 
including methylation, N-terminal acetylation, acylation, arginylation and 
phosphorylation of several serine, threonine and thyrosine residues but this 
study is the first one to show proline hydroxylation. The hydroxylation of actin 
was shown to have an effect on the organisation of the actin cytoskeleton as 
well as on cell migration.  
As shown in chapter 3, a substrate can be trapped on the PHD enzyme under 
hypoxia suggesting that PHDs function by a similar binding mechanism to the one 
described for other -ketoglutarate-dependent oxygenases [30]. In a 
quantitative proteomic approach actin was identified as a possible substrate of 
PHDs. The specific interaction of PHD3 and -actin was confirmed in chapter 4. 
PHD3 was the only isoform strongly binding to -actin specifically under hypoxia. 
Subsequently -actin was found to be hydroxylated at Pro70 and Pro322. The 
hydroxylated prolyl residues lie within sequences resembling the LXXLAP binding 
motif described in the literature for HIF1 [53], even though one or both leucine 
residues are replaced by the structurally similar isoleucine. In 
immunofluorescence experiments, PHD3 did not co-localise with actin stress 
fibres but rather with more diffuse actin patterns. However a rearrangement of 
the actin cytoskeleton was observed under hypoxia. In chapter 5 the biological 
function of the interaction between actin and PHD3 was investigated in more 
detail. Hypoxia-induced changes in the actin cytoskeleton were found to be 
dependent on PHD3 activity. Knockdown of PHD3 was sufficient to increase 
intracellular G-actin levels and decrease intracellular F-actin levels. Hypoxia-
induced cell migration and invasion were dependent on the loss of PHD3 activity 
as well. Both hydroxylated prolyl residues in -actin (Pro70 and Pro322) appear 
to be important, however this needs to be investigated further. Mutation of both 
prolyl residues to alanine led to rearrangement of the actin cytoskeleton as well 
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as increased cell migration. Single mutations had a lesser effects on actin 
organisation and cell migration. 
Therefore, our current working model is as follows (Figure 6.1): PHD3-dependent 
hydroxylation of actin is important for the maintenance of the intracellular G- to 
F-actin ratio as hydroxylated actin is incorporated into actin filaments and 
stabilises them. Reduction of PHD3 activity leads to an increase in the 
intracellular G- to F-actin ratio, rearrangement of the actin cytoskeleton and 
increase in cell migration and invasion. 
 
 
 
Figure 6.1: Working model of how PHD3 regulates the actin cytoskeleton (as described in 
the text) 
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Taken together, our results suggest a new signalling mechanism for actin 
polymerisation and it is the first study to describe how oxygen-sensing pathways 
are able to interact directly with the actin cytoskeleton. However, some 
questions still remain unanswered: Is the hydroxylation of actin solely dependent 
on PHD3 or are there other prolyl hydroxylases involved as well? How does actin 
get de-hydroxylated under hypoxia? Do PHD3 and actin directly interact? How 
does the hydroxylation of actin effect the polymerisation of actin? And what is 
the mechanism that leads from actin cytoskeleton rearrangement to an increase 
in cell migration and invasion? 
A crucial point to elucidate the mechanism is to prove, that actin is truly 
hydroxylated by PHD3. It is technically challenging to identify hydroxylation sites 
and no systematic approach has been developed yet to do so. As there are no 
hydroxyproline specific antibodies available at the moment, the only method to 
identify hydroxylation sites is by mass spectrometry. In this study we used a 
mass spectrometric based method described by Unwin [122] to identify 
hydroxylation sites. Using this method we are currently trying to find differences 
in actin hydroxylation in PHD3 knockdown and knockout cells compared to 
wildtype cells. As about 10% of actin is hydroxylated under normoxia, it suggests 
a role of hydroxylation in actin signalling. However, the percentage of 
hydroxylated actin under hypoxia should be analysed. Furthermore, it would be 
interesting to know how and how quickly actin is de-hydroxylated. So far no de-
hydroxylase has been identified and other proteins that are hydroxylated such as 
HIF1 are targeted for proteasomal degradation making dehydroxylation 
unnecessary. In our case we do not have evidence supporting either the 
dehydroxylation or the degradation of actin, but it would be interesting to find 
out what happens to hydroxylated actin under hypoxia. Most of the HIF-
dependent hypoxic response is due to gene transcription even though 
HIF1accumulates within minutes after exposure to hypoxia and degrades as 
quickly after reoxygenation. The fact that a short treatment of 1 hour with 
DMOG has an effect on the actin cytoskeleton, suggests that regulation other 
than transcription is important in this case. 
PHD3 was identified to interact withactin and the results in this study are 
mostly based on -actin. However, in the SILAC screen -actin was identified as a 
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potential substrate of PHDs as well. The sequences of - and -actin are 98% 
identical and the prolyl residues found to be hydroxylated in -actin are 
conserved in -actin as well as in -actin. As differences in the functions of actin 
isoforms have been proposed [109], it would be interesting to investigate these 
other actin isoforms and their potential to interact with PHD3. Preliminary 
experiments using Fluorescent Lifetime Imaging Microscopy (FLIM) were 
performed to investigate the intracellular location and interaction of PHD3 and 
-actin in more detail (data not shown). The fluorescent lifetime of a 
fluorophore is the time an electron remains in the excited state before returning 
to the ground state while emitting a photon. This time is characteristic for every 
fluorophore, but can be altered by its local environment. Interaction with 
another fluorophore leading to energy transfer to the acceptor fluorophore 
decreases the lifetime of a donor fluorophore, a process called Fluorescence 
Resonance Energy Transfer (FRET). The efficiency of the energy transfer is 
dependent on the distance between the two molecules. Detection of FRET 
between two proteins fused to appropriate fluorophores (a donor and an 
acceptor) indicates their interaction [129]. In these preliminary experiments a 
lifetime shift was observed when PHD3 localised to actin bundles under 
normoxia, but further analyses are needed to identify where in the cell and 
under which conditions PHD3 and actin interact. Furthermore, it would be 
important to determine, if PHD3 binds to actin monomers or actin filaments 
either directly or indirectly using in vitro binding studies.  
Hydroxylated actin seems to be targeted to the filaments, however many 
questions remain to be elucidated: how does hydroxylated actin stabilise actin 
filaments and how des it effect polymerisation? Does hydroxylated actin localise 
at specific sites within the filaments or lead to binding of specific proteins? Does 
it influence nucleation or the release of phosphate within the filament? The 
effect of actin hydroxylation on filament stability and turn-over should be tested 
with biochemical assays. However, the position of the hydoxylated prolyl 
residues could give some implications for a signalling mechanism (Figure 6.1): 
Pro70 is located in subdomain 2 close to the ATP-binding site of actin, possibly 
influencing nucleotide exchange. Pro322 is located in subdomain 3, which could 
influence actin polymerisation as subdomain 1 and 3 comprise the (+) end of 
actin. Binding of a number of actin binding proteins influencing actin signalling 
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pathways could be affected. As RhoA activity and phosphorylation of myosin 
light chains are important for the formation of actin stress fibres, it would be 
interesting to investigate PHD3-dependent changes in this signalling cascade. 
Recently PHD2 has been described to be able to regulate the RhoA/ROCK/cofilin 
pathway [130]. 
The next question is how actin rearrangement is linked to an increase in cell 
migration and invasion. As discussed in chapter 1, hypoxia has been described to 
affect several pathways that are important for invasion and metastasis [88, 90-
92]. However most of the pathways described seem to be HIF-dependent. A 
rearrangement of the actin cytoskeleton under hypoxia was reported previously 
where an increase in central stress fibres was observed using phalloidin-staining 
[130-132]. However changes in the actin cytoskeleton were not investigated in 
more detail. For efficient actin based cell migration fine tuning of intracellular 
G- and F-actin levels is important as was shown in chapter 5, when increasing 
concentrations of latrunculin A were used and the rate of cell migration was 
monitored. However, for efficient cell migration not only protrusion but also 
retraction of the cell body is needed [100, 101]. Retraction is mediated by 
actomyosin contractility and stress fibres. As discussed in chapter 1, different 
cell types are able to invade in different modes and are able to switch between 
mesenchymal or amoeboid invasion depending on the microenvironment [97, 
98]. A375 cells tend to invade in an amoeboid fashion but the effect on PHD3 on 
migration should be tested in cell lines invading in a mesenchymal mode as well.  
In our studies migration on a plastic dish appears to be solely dependent on 
PHD3 and independent of HIF. However, invasion into a 3D environment (as is 
the situation in vivo) is more complex and requires several independent 
mechanisms some of which are HIF-dependent [88, 90-92]. Our results hint to an 
involvement of HIF-independent pathways downstream of PHD3 which are less 
well understood. It could be interesting to look at a combination of PHD 
knockdowns and their effect on invasion. Furthermore it would be important to 
investigate the in vivo function of the interaction between PHD3 and actin and 
to investigate the potential anti-metastatic role of PHD3 in PHD3-/- mice. 
Tumour hypoxia is linked to resistance to radio- and chemotherapies as well as 
increase in metastatic potential [13, 14]. As HIF is activated in a variety of 
tumours affecting a number of pathways, a lot of effort has been made to 
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develop HIF inhibitors or inhibitors for specific HIF target genes such as VEGF 
which stimulates angiogenesis [7, 12, 133]. However, as shown in this study 
there are HIF-independent pathways controlling cell migration and metastasis 
under hypoxia, but few agents are available that directly modulate PHD activity 
and hence target the oxygen-sensing pathways upstream of HIF [128, 134].  
In this study the role of PHD3 activity in actin cytoskeleton rearrangement and 
its role in regulating hypoxia-induced cell migration were investigated. -actin 
was identified as potential substrate of PHD3, and subsequently found to be 
hydroxylated at two specific prolyl residues needed for regulating actin 
cytoskeleton and cell migration. 
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